proline and Hepatitis C

proline has been researched along with Hepatitis C in 339 studies

Research

Studies (339)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (0.29)	18.2507
2000's	16 (4.72)	29.6817
2010's	272 (80.24)	24.3611
2020's	50 (14.75)	2.80

Authors

Authors	Studies
Brown, A; Colombo, M; Crown, E; Dillon, JF; Dylla, DE; Feld, JJ; Ghalib, R; Hu, Y; Jacobson, IM; Lawitz, E; Lovell, SS; Luetkemeyer, AF; Moreno, C; Mutimer, D; Nelson, DR; Papatheodoridis, G; Rockstroh, JK; Skoien, R; Zamor, PJ	1
Bair, MJ; Chang, CC; Chang, TS; Chen, CT; Chen, CY; Chen, GY; Cheng, CY; Cheng, PN; Chong, LW; Chuang, WL; Dai, CY; Hsieh, TY; Hu, JT; Huang, CF; Huang, CS; Huang, CW; Huang, JF; Huang, YH; Hung, CH; Kao, CN; Kao, JH; Kuo, HT; Lee, MH; Lee, PL; Lee, TH; Lin, CL; Lin, HC; Liu, CJ; Lo, CC; Mo, LR; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tseng, KC; Wang, CC; Wang, SJ; Wu, WC; Yang, CC; Yang, SS; Yeh, ML; Yu, ML	1
Li, J; Liu, J; Ma, HX; Wang, CY; Wen, J	1
Alexander, G; Alric, L; Busch, MP; Carrington, M; Chung, RT; Cox, AL; Cramp, ME; Donfield, SM; Douillard, V; Duggal, P; Edlin, BR; Goedert, JJ; Gourraud, PA; Grifoni, A; Johnson, EO; Khakoo, SI; Kim, AY; Kirk, GD; Kral, AH; Lauer, GM; Mangia, A; Mehta, SH; Murphy, EL; Piazzolla, V; Price, JC; Rosen, HR; Sette, A; Thio, CL; Thomas, DL; Valencia, A; Vergara, C; Vince, N; Wojcik, GL	1
Chang, YL; Chou, YC; Hsu, CC; Huang, YH; Huang, YY; Loong, CC; Wu, TH	1
Bansal, S; Giacomet, V; Hsueh, CH; Indolfi, G; Iorio, R; Kelly, D; Kersey, K; Mangia, A; Mania, A; Nebbia, G; Parhy, B; Pawlowska, M; Sang Yue, M; Shao, J; Szenborn, L	1
Christensen, PB; Du, Y; Khera, T; Lillevang, ST; Madsen, LW; Wedemeyer, H	1
Öksüz, Z; Serin, MS; Sezgin, O; Temel, GÖ; Üçbilek, E; Yaraş, S	1
Ando, H; Atsukawa, M; Ikejima, K; Nagahara, A; Nakadera, E; Okubo, H; Okubo, T	1
Chen, JJ; Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC; Lee, PL; Tung, HD	1
Ar, C; Bozcan, S; Canbakan, B; Gültürk, İ; Hatemi, İ; Özdemir, S; Sonsuz, A; Yıldırım, S	1
Collado, A; Corma-Gomez, A; Cucurull, J; Gonzalez-Serna, A; Granados, R; Hernandez-Quero, J; Macias, J; Merino, D; Palacios, R; Pineda, JA; Real, LM; Rios, MJ; Rivero-Juarez, A; Tellez, F	1
Hui, VK; Kao, JH; Kumar, R; Liu, CH; Tan, J; Tan, SS; Thurairajah, PH; Wong, GH; Wong, YJ	1
Chuang, WL; Dai, CY; Huang, CF; Huang, JF; Yu, ML	1
Chen, SF; Joerger, T; Kushner, LE; Lee, J; Profita, E; Puckett, L	1
Chang, KC; Chang, TS; Chen, CH; Chen, WM; Chen, YH; Hsieh, YY; Hung, CH; Lu, CK; Lu, SN; Lu, YH; Tung, SY; Tung, WL; Yen, CW	1
Barclay, ST; Bradley-Stewart, A; Davis, C; Filipe, A; Fox, R; Gunson, R; MacLean, A; Ngan Chiu Bong, M; Peters, ES; Shah, R; Shepherd, SJ; Thomson, EC; Tong, L; van Vliet, VJE	1
Akarca, US; Danış, N; Ersöz, G; Günşar, F; Karasu, Z; Özkahya, M; Toz, H; Turan, İ; Ünal, N; Yılmaz, M	1
Aghemo, A; Asselah, T; Bräu, N; Brown, A; Chen, YJ; Conway, B; Grebely, J; Kleine, H; Lawitz, E; Lei, Y; Mensa, FJ; Negro, F; Pugatch, D; Puoti, M; Welzel, TM	1
Chaparro, M; García-Buey, L; Rojo, E	1
Cescon, M; De Pace, V; Galli, S; Maggi, F; Morelli, MC; Pistello, M; Ravaioli, M; Re, MC; Vero, V	1
Alston-Smith, BL; Cohen, DE; Cramer, YS; Morse, GD; Rosenkranz, SL; Schmidt, J; Sulkowski, M; Venuto, CS; Wyles, DL	1
Baka-Ćwierz, B; Belica-Wdowik, T; Białkowska, J; Buczyńska, I; Citko, J; Czauż-Andrzejuk, A; Deroń, Z; Dobracka, B; Dybowska, D; Flisiak, R; Garlicki, A; Halota, W; Janczewska, E; Jaroszewicz, J; Klapaczyński, J; Krygier, R; Laurans, Ł; Lorenc, B; Mazur, W; Pabjan, P; Pawłowska, M; Piekarska, A; Simon, K; Sitko, M; Tomasiewicz, K; Tronina, O; Tudrujek-Zdunek, M; Zarębska-Michaluk, D	1
Aguilar, H; Asatryan, A; Bondin, M; Cacoub, P; Carvalho, A; Castro, RE; Charafeddine, M; Cohen, DE; Dieterich, D; Felizarta, F; Hu, YB; Khan, N; Marinho, RT; Poordad, F; Siddique, A	1
Abu Hassan, MR; Gonzalez, YS; Ong, SC; Shafie, AA; Virabhak, S	1
Angelico, M; Aragri, M; Carioti, L; Ceccherini-Silberstein, F; Di Maio, VC; Lenci, I; Milana, M; Perno, CF; Svicher, V	1
Ben-Ari, Z; Bruck, R; Cohen-Ezra, O; Deutsch, L; Gozlan, Y; Houri, I; Issachar, A; Katchman, H; Menachem, Y; Mor, O; Shibolet, O; Shlomai, A; Veitsman, E; Zelber-Sagi, S	1
Hasegawa, K; Kinoshita, A; Kobayashi, Y; Koike, K; Mizuno, Y; Nakata, R; Ogata, I; Shiraishi, K; Yamada, N; Yasuda, K; Yoshida, H	1
Chang, TS; Chen, CH; Chen, MY; Chen, WM; Chiu, WN; Hu, JH; Hu, TH; Hung, CH; Lu, CK; Lu, SN; Tung, SY; Wei, KL	1
Maasoumy, B; Ohlendorf, V	1
Khalil, H; Kim, NG; Kullar, R; Saab, S	1
Agarwal, K; Bestwick, J; Drysdale, K; Elsharkawy, AM; Forton, D; Foster, GR; Gelson, W; Mahomed, F; Mutimer, D; Ntuli, Y; Townley, C	1
Fargnoli, A; Gidea, CG; Jacobson, I; Kon, Z; Lewis, T; Lonze, B; Moazami, N; Pavone, J; Qian, Y; Rao, S; Reyentovich, A; Saraon, T; Smith, D	1
Abergel, A; Asselah, T; Fredrick, LM; Gane, E; George, C; Hung Le, M; Kowdley, KV; Kwo, PY; Lee, SS; Mensa, F; Nguyen, K; Nguyen, T; Pham, TT; Poordad, F; Schnell, G; Spearman, CW; Wong, F; Yao, BB	1
Da, BL; Dieterich, D; Kushner, T; Lourdusamy, V; Saberi, B	1
Caruntu, F; Cohen, S; de Ledinghen, V; Dillon, JF; Dylla, DE; Fredrick, LM; Gschwantler, M; Gutierrez, JA; Muir, AJ; Nevens, F; Pires Dos Santos, AG; Puoti, M; Rodrigues, L; Sigal, S; Slim, J; Zuckerman, E	1
Angel, L; Gidea, C; Kon, Z; Lesko, M; Lewis, TC; Moazami, N; Pavone, J; Reyentovich, A; Smith, DE; Sureau, K	1
De Clercq, E; Jing, X; Li, G; Miao, M	1
Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y	1
Alloway, RR; Aull, MJ; Barnaba, B; Belshe, DS; Brown, RS; Chung, RT; Desai, NM; Doshi, M; Durand, CM; Elias, N; Fernando, M; Fontana, RJ; Friedewald, JJ; Goldberg, DS; Gustafson, JL; Kort, JJ; Landis, JR; Levitsky, J; Norman, SP; Phillips, CC; Prenner, S; Reese, PP; Rike-Shields, A; Schaubel, DE; Sherman, KE; Sise, ME; Sultan, ST; Williams, WW; Woodle, ES	1
Ahlenstiel, G; Bowden, S; Dore, GJ; Douglas, M; Doyle, J; Farrell, G; Fisher, L; George, J; Haque, M; Hazeldine, S; Hellard, M; Levy, M; MacQuillan, G; McGarity, B; New, K; O'Beirne, J; O'Keefe, J; Papaluca, T; Prewett, E; Roberts, SK; Sawhney, R; Sievert, W; Sinclair, M; Sood, S; Stoove, M; Strasser, SI; Stuart, KA; Thomas, J; Thompson, AJ; Tse, E; Valaydon, Z; Valiozis, I; Wade, AJ; Weltman, M; Wigg, A; Wilson, M; Woodward, A	1
Berg, T; Heyne, R; John, C; Klinker, H; Naumann, U; Niederau, C; Serfert, Y; Stein, K; Stoehr, A; Teuber, G; Wiegand, J; Zeuzem, S	1
Aho, I; Amele, S; Bhagani, S; Chkhartisvili, N; Clarke, A; Domingo, P; Falconer, K; Fonquernie, L; Jabłonowska, E; Leen, C; Lundgren, J; Maltez, F; Matulionyte, R; Mocroft, A; Peters, L; Rockstroh, J; Rodger, A; Sarcletti, M; Stephan, C; Szlavik, J; Wandeler, G; Zaccarelli, M; Østergaard, L	1
Berak, H; Białkowska-Warzecha, J; Buczyńska, I; Citko, J; Deroń, Z; Dobracka, B; Dybowska, D; Flisiak, R; Halota, W; Horban, A; Janczewska, E; Jaroszewicz, J; Klapaczyński, J; Krygier, R; Laurans, Ł; Lorenc, B; Mazur, W; Pabjan, P; Pawłowska, M; Piekarska, A; Simon, K; Sitko, M; Sobala-Szczygieł, B; Socha, Ł; Tomasiewicz, K; Tronina, O; Tudrujek-Zdunek, M; Zarębska-Michaluk, D; Łapiński, TW	1
Crehuá Gaudiza, E; Quintero García, D; Sebastián Cuevas, FJ	1
Babudieri, S; Barbarini, G; Dell'Isola, S; Fiore, V; Madeddu, G; Marri, D; Pontali, E; Prestileo, T; Ranieri, R; Sotgiu, G; Starnini, G	1
Erren, P; König, B; Lohmann, K; Mauss, S; Naumann, U; Rieke, A; Stoehr, A; Wedemeyer, H; Zimmermann, T	1
Ebata, K; Hirata, K; Katagiri, M; Nakajima, S; Ozasa, M; Sakamoto, N; Sasaki, T; Suda, G; Takahash, S; Takano, M; Tsukamoto, S; Umemura, M	1
Berg, T; Bondin, M; Cornberg, M; Klinker, H; Koenig, B; Lohmann, K; Naumann, U; Rössle, M; Zeuzem, S	1
Bondin, M; Brown, A; Burroughs, M; Chayama, K; Dylla, DE; Emmett, A; Feld, JJ; Forns, X; Gordon, SC; Heo, J; Hou, J; Jacobson, IM; Lampertico, P; Marcinak, J; Pol, S; Tatsch, F; Zhang, Z	1
Andrade, RJ; Calleja, JL; Calvo, M; Delgado, MB; Frias, YN; Gálvez-Fernández, RM; Gómez, J; López, MA; Manzano, ML; Molina, E; Olveira, A; París, S; Rincón, D; Rosales, JM; Salmerón, FJ; Santos de Lamadrid, R; Turnes, J; Vallejo-Senra, N	1
Adeyemi, O; Bhatti, L; Hu, YB; Khatri, A; King, JR; Lalezari, J; Ruane, P; Saag, M; Shulman, NS; Trinh, R; Viani, RM; Wyles, D	1
Cheng, K; Chevaliez, S; Cloherty, G; Cohen, DE; Dawson, GJ; Feld, JJ; Hackett, J; Herman, C; Maasoumy, B; Pawlotsky, JM; Rockstroh, JK; Sarrazin, C; Wedemeyer, H	1
Bolewska, B; Buivydiene, A; Durlik, M; Flisiak, R; Jabłkowski, M; Jakutiene, J; Karpińska, E; Karwowska, KM; Katzarov, K; Kupcinskas, L; Pisula, A; Rostkowska, K; Simonova, M; Tolmane, I; Tronina, O; Wawrzynowicz-Syczewska, M	1
Bollipo, S; Cheng, W; Chivers, S; Dore, G; Fragomeli, V; Galhenage, S; Gazzola, A; George, J; Gow, P; Iser, D; Jones, T; Levy, M; Lubel, J; MacQuillan, G; Mitchell, JL; Nazareth, S; Pianko, S; Roberts, SK; Sasadeusz, J; Strasser, S; Stuart, KA; Thompson, A; Tse, E; Wade, A; Weltman, M; Wigg, A; Zekry, A	1
Bao, Y; Calleja, JL; Craxí, A; Dieterich, D; Flisiak, R; Martinez, M; Pangerl, A; Roberts, SK; Wedemeyer, H; Zhang, Z; Zuckerman, E	1
Alves, K; Burroughs, M; Chayama, K; Kato, K; Kumada, H; Pilot-Matias, T; Redman, R; Rodrigues, L; Sato, K; Setze, C; Suzuki, F; Toyoda, H; Zhang, X	1
Bansal, MB; Bourlière, M; Brainard, DM; Buggisch, P; Cooper, CL; Curry, MP; de Lédinghen, V; Dvory-Sobol, H; Flamm, SL; Gordon, SC; Huang, KC; Hyland, RH; Kowdley, KV; Landis, CS; Manns, MP; McHutchison, JG; Pianko, S; Ramji, A; Ravendhran, N; Reddy, KR; Schiff, ER; Stamm, LM; Strasser, SI; Subramanian, GM; Svarovskaia, E; Tong, M; Tran, TT; Verna, EC; Vierling, JM; Younes, ZH; Zeuzem, S; Zhang, J	1
Amemiya, M; Hayashi, N; Koshima, Y; Kuriyama, S; Matsuyama, M; Morisawa, N; Satoh, JI; Yokoo, T	1
Chen, PJ; Chuang, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, CI; Huang, JF; Kao, JH; Liu, CJ; Liu, TW; Su, TH; Wang, SC; Yeh, ML; Yu, ML	1
Bellissant, E; Ben Ali, Z; Boglione-Kerrien, C; Guyader, D; Jezequel, C; Lemaitre, F; Tron, C; Verdier, MC	1
Arias, A; Barreiro, P; Benítez-Gutiérrez, L; Carrasco, I; de Mendoza, C; Peña, JM; Soriano, V	1
Aguilar, H; Felizarta, F; Forns, X; Ghalib, R; Hassanein, T; Hinrichsen, H; Horsmans, Y; Kort, JJ; Krishnan, P; Lee, SS; Lens, S; Lin, CW; Mensa, FJ; Morillas, R; Nelson, DR; Rincon, D; Valdes, J; Yu, Y; Zeuzem, S	1
Abunimeh, M; Agarwal, K; Charafeddine, M; Cohen, DE; Cohen, E; Foster, GR; Fu, B; Gane, E; Pilot-Matias, T; Pothacamury, RK; Shafran, SD; Shaw, D	1
Rostkowska, K; Simon, K; Szymanek-Pasternak, A	1
Arama, V; Brisc, C; Caruntu, F; Cijevschi, C; Curescu, M; Gheorghe, C; Gheorghe, L; Iacob, R; Iacob, S; Simionov, I; Sirli, R; Sporea, I; Stanciu, C; Trifan, A	1
Chodick, G; Koren, G; Mehta, D; Pinsky, B; Samp, JC; Shalev, V; Weil, C	1
Birnkrant, D; Chan-Tack, K; Naeger, LK; Qi, K; Struble, K	1
Brainard, DM; Cheng, G; Dvory-Sobol, H; Lawitz, E; Miller, MD; Mo, H; Stamm, LM; Taylor, JG; Yang, JC	1
Aschenbrenner, DS	1
Chahine, EB; Childs-Kean, LM; Kelley, D	1
Li, GF; Yu, G; Zhou, HH	1
Forns, X; Mensa, FJ	1
Kurt Yilmaz, N; Matthew, AN; Schiffer, CA	1
Buti, M; Chen, Q; Esteban, JI; Esteban, R; Garcia-Cehic, D; Gregori, J; Llorens, M; Nieto-Aponte, L; Ordeig, L; Perales, C; Quer, J; Riveiro-Barciela, M; Rodriguez-Frias, F; Soria, ME	1
Collins, MG; Kort, J; Kosloski, MP; Liu, W; Marbury, TC; Mensa, F; Preston, RA; Pugatch, D; Zhao, W	1
Hirayama, T; Honda, A; Ikegami, T; Kohjima, M; Matsuzaki, Y; Miyazaki, T; Nakamuta, M; Yara, SI	1
Bao, Y; Grunow, N; Hudgens, S; Mehta, D; Pinsky, B; Saab, S	1
Muñoz-Medina, L; Navarro-Navarro, I; Navarro-Triviño, FJ; Ruiz-Villaverde, R	1
Bernstein, DE; Feld, JJ; Ferenci, P; Larsen, L; Tatsch, F; Vlierberghe, HV; Younes, Z	1
Huang, F; Rowland, L; Sabo, JP; Schultz, A; Trampisch, M; Voelk, C	1
Collado, A; de Los Santos, I; Macías, J; Mancebo, M; Merino, D; Morano-Amado, LE; Palacios, R; Pérez, AB; Pérez-Pérez, M; Pineda, JA; Ríos, MJ; Rivero, A; Rivero-Juárez, A; Téllez, F	1
Cao, Y; Chen, D; Gai, K; Liu, B; Liu, X; Lu, D; Lu, Q; Qin, H; Shen, H; Song, W; Wang, X; Xu, H; Zhang, Y	1
Andreoni, M; Antinori, A; Bigoni, S; Boffa, N; Borghi, V; Bovis, F; Bruno, R; Cacopardo, B; Cattelan, A; Chirianni, A; D'Arminio Monforte, A; Di Biagio, A; Di Perri, G; Giacometti, A; Gori, A; Gubertini, G; Hasson, H; Mastroianni, C; Milazzo, L; Montagnani, F; Nicolini, LA; Niero, F; Parruti, G; Pasquazzi, C; Puoti, M; Saracino, A; Segala, D; Sollima, S; Spinetti, A; Taliani, G; Taramasso, L; Teti, E; Vullo, V	1
Carrion, AF; Martin, P	1
Kjellin, M; Lannergård, A; Lennerstrand, J; Löfblad, E; Wesslén, T	1
Forde, KA; Sawinski, D; Wyatt, CM	1
Applegate, TL; Bhagani, S; Cooke, G; Dore, GJ; Gane, E; Grebely, J; Marks, P; Martinello, M; Matthews, GV; Nelson, M; Orkin, C; Pagani, N; Petoumenos, K; Tu, E	1
Ando, H; Fukada, H; Ikejima, K; Miyazaki, A; Morishige, J; Nakadera, E; Okubo, H; Sorin, Y	1
Summers, BB	1
Hsu, CS; Wu, CC	1
Kottilil, S; Mathur, P; Wilson, E	1
Arias, M; Belmar, L; González, LN; Laguno, M; Llovet, LP; Londoño, MC; Maduell, F; Mallolas, J; Martínez-Rebollar, M; Ojeda, R; Rodas, L; Rossi, F; Ugalde, J	1
Lee, TY; Yang, SS	1
Hsiang, JC; Kumar, R; Tan, J; Thurairajah, PH	1
Kubo, T; Nanmoku, K; Shimizu, T; Shinzato, T; Yagisawa, T	1
Bladowska, J; Ejma, M; Fleischer-Stępniewska, K; Inglot, M; Knysz, B; Marciniewicz, E; Małyszczak, K; Pawłowski, T; Podgórski, P; Rymer, W; Sąsiadek, M; Waliszewska-Prosół, M; Żelwetro, A	1
Balibrea, N; Franco, A; Gimeno, A; Kanter, J; Merino, E; Moreso, F; Perez Contreras, F; Rodriguez, M; Sancho, A	1
Brown, A; Dufour, JF; Gordon, SC; Mauss, S; Mensa, FJ; Pilot-Matias, T; Poordad, F; Rodrigues, L; Stoehr, A; Weiland, O; Weilert, F; Wyles, D; Yao, B; Zhang, Z	1
Kiser, JJ	1
Chen, CY; Chen, DS; Chen, PJ; Cheng, PN; Chiu, YC; Fang, YJ; Hsieh, TY; Kao, JH; Lin, CL; Liu, CH; Liu, CJ; Peng, CY; Shih, YL; Su, TH; Yang, HC; Yang, SS	1
Aghemo, A; Parigi, TL; Torres, MCP	1
Angulo-Diaz, V; Lim, JK; Mandimika, C; Maughan, A; Ogbuagu, O; Sadigh, K; Villanueva, M	1
Barzegari, E; Behmard, E	1
Arai, T; Asai, A; Asano, T; Atsukawa, M; Fukunishi, S; Hayama, K; Hiraoka, A; Iio, E; Ikeda, H; Ikegami, T; Itokawa, N; Iwakiri, K; Kato, K; Kikuchi, K; Kondo, C; Kumada, T; Matsumoto, N; Matsumoto, Y; Mikami, S; Moriya, A; Nakamuta, M; Nozaki, A; Ogawa, C; Oikawa, T; Okubo, H; Okuse, C; Shimada, N; Tachi, Y; Tada, T; Takaguchi, K; Tanaka, Y; Tani, J; Toyoda, H; Tsubota, A; Tsuruoka, S; Tsutsui, A; Uojima, H; Watanabe, T; Yamashita, N	1
Alados-Arboledas, JC; Aldámiz-Echevarría, T; Casado, M; Chueca, N; García, F; García-Bujalance, S; García-Deltoro, M; Lara-Pérez, MM; Martínez-Sapiña, AM; Merino, D; Pascasio, JM; Pérez, AB; Pineda, JA; Poyato, A; Rivero-Juárez, A; Rosales-Zábal, JM; Salmerón, J; Téllez, F; Vera-Méndez, FJ; Vivancos-Gallego, MJ	1
Boglione, L; Bonora, S; Calcagno, A; De Rosa, FG; Di Perri, G	1
Barry, MG; Bergin, C; Kieran, JA; Norris, S; O'Leary, A; Schmitz, S; Walsh, C	1
Blonk, MI; Burger, DM; Colbers, AP; de Kanter, CT; Drenth, JP; Schouwenberg, BJ; Verweij-van Wissen, CP	1
Nikitin, AV	1
Agnesod, D; Boglione, L; Cariti, G; D'Avolio, A; De Nicolò, A; Di Perri, G; Dilly Penchala, S; Mohamed Abdi, A; Simiele, M	1
Coffield, DJ; Dahari, H; Guedj, J; Levi, M; Perelson, AS; Rong, L; Smith, P	1
Cobb, B; Pockros, PJ; Vierling, JM; Vilchez, RA	1
Crespo, G; Forns, X; Londoño, MC	1
Giguere, P; Sockalingam, S; Tseng, A; Wong, D	1
Aqel, BA; Charlton, MR; Henry, TM; Keaveny, AP; Koning, L; Murphy, JL; Pungpapong, S; Rosser, BG; Ryland, KL; Satyanarayana, R; Vargas, HE; Yataco, ML	1
Gunson, RN; Leitch, EC; McNaughton, AL; Templeton, K; Thomson, EC	1
Al-Ibrahim, M; Barnard, R; Caro, L; Gordon, SC; Gress, J; Hwang, PM; Jacobson, I; Kraft, WK; Kwo, P; Lawitz, E; Maliakkal, B; Miller, M; Mobashery, N; Panorchan, P; Quirk, E; Rockstroh, JK; Sulkowski, M	1
Balart, L; Box, T; Brunda, M; Buggisch, P; Cooper, C; Ferenci, P; Hooper, G; Labriola-Tompkins, E; Larrey, D; Lawitz, E; Le Pogam, S; Lim, CY; Marcellin, P; Nájera, I; Navarro, MT; Shulman, NS; Terrault, NA; Thomas, D; Weltman, M; Yetzer, ES; Yoshida, E; Zhang, Y	1
Andonov, A; Kadkhoda, K; Kaita, K; Osiowy, C	1
Euliano, R; Juneja, M; Lewis, JH; Satoskar, R	1
Rotella, DP	1
Serfaty, L	1
Chiari, E; Cocca, G; Moioli, MC; Morreale, M; Orso, M; Panzeri, C; Puoti, M; Rossotti, R; Travi, G	1
Colombo, M; D'Ambrosio, R	1
Morgan, TR; O'Brien, TR; Pfeiffer, RM; Wang, AS	1
Bichoupan, K; Dieterich, DT; Martel-Laferrière, V	1
Liu, CJ	1
Backus, LI; Belperio, PS; Cheung, R; Mole, LA; Shahoumian, TA	1
Pol, S	1
Baka, M; Dyda, T; Opoka-Kegler, J; Stańczak, GP; Stańczak, JJ; Zabek, P	1
Adhoute, X; Ansaldi, C; Bourlière, M; Castellani, P; Oules, V; Wendt, A	1
Boccaccio, V; Bruno, S	1
Coilly, A; Duclos-Vallée, JC; Roche, B; Samuel, D	1
Dieterich, DT; Martel-Laferrière, V	1
Asselah, T; Marcellin, P	1
Asselah, T; Halfon, P; Marcellin, P; Schinazi, R	1
Ford, N; Fortunak, J; Hill, A; Khoo, S; Simmons, B	1
Dekio, F; Malik, S; Wen, JW	1
Andreone, P; Beltran-Jaramillo, T; Brunda, M; Bruno, S; Cooper, C; Everson, G; Ferenci, P; Hézode, C; Le Pogam, S; Nájera, I; Navarro, MT; Shiffman, ML; Shulman, NS; Voulgari, A; Yetzer, ES; Yoshida, E; Zeuzem, S; Zhou, J	1
Carrion, AF; Gutierrez, J; Martin, P	1
Gutierrez, JA; Wyles, DL	1
Chung, RT; deLemos, AS	1
Andronescu, CI; Andronescu, D; Diaconu, S; Purcarea, RM; Tiuca, N	1
Backus, LI; Belperio, PS; Mole, LA; Shahoumian, TA	1
Allen, R; Bau, S; Busuttil, RW; Durazo, F; El-Kabany, M; Goldstein, L; Han, S; Manne, V; Reynolds, JA; Saab, S	1
Kong, DC; Neoh, CF	1
Asselah, T; Berg, T; Böcher, WO; Datsenko, Y; Dieterich, D; Ferenci, P; Guyader, D; Larrey, D; Maieron, A; Mauss, S; Ozan, M; Ratziu, V; Schuchmann, M; Steinmann, G; Stern, JO	1
Bacon, BR; Baruch, Y; Bruno, S; Caro, L; Cooreman, MP; Dutko, FJ; Fandozzi, C; Gilbert, CL; Gress, J; Howe, AY; Hwang, P; Manns, MP; Marcellin, P; Mobashery, N; Robertson, MN; Shaw, PM; Shibolet, O; Vierling, JM; Wahl, J	1
Brown, RS; Burton, JR; Dodge, JL; Everson, GT; Levitsky, J; O'Leary, JG; Saxena, V; Stravitz, RT; Terrault, NA; Trotter, JF; Verna, EC	2
Berg, T; Buggisch, P; Buslau, A; Hinrichsen, H; Maasoumy, B; Sarrazin, C; Schiefke, I; Wedemeyer, H; Wiegand, J	1
Ballester, R; Bernaards, C; Bertasso, A; Dwyer, C; Gane, EJ; Hammond, J; Kindrick, A; Marcellin, P; Morcos, PN; Nájera, I; Pockros, PJ; Shikhman, A; Shulman, NS; Smith, P; Stancic, S; Tong, X; Yetzer, ES; Zeuzem, S; Zhou, J	1
Abergel, A; Boyer, A; Lamblin, G; Sautou, V; Talavera Pons, S	1
Andreone, P; Bernstein, B; Colombo, MG; Enejosa, JV; Ferenci, P; Horsmans, Y; Hu, YB; Koksal, I; Maieron, A; Müllhaupt, B; Podsadecki, T; Reesink, HW; Rodrigues, L; Weiland, O	1
Barth, H; Baumert, TF; Bukh, J; Doffoël, M; Fofana, I; Habersetzer, F; Heydmann, L; Patel, AH; Soulier, E; Xiao, F; Zeisel, MB	1
Lawitz, EJ; Membreno, FE	1
Backus, LI; Belperio, PS; Mole, LA; Neuhauser, MM; Ross, D	1
Bichoupan, K; Dieterich, DT	1
Brown, RS; Dove, LM; Fox, AN; Lukose, T; Mentore, K; Olsen, SK; Shetty, K; Terry, N; Verna, EC	1
Borgia, G; Buonomo, AR; Gentile, I; Zappulo, E	1
Corouge, M; Pol, S	1
Thompson, JR	1
Asselah, T; Boyer, N; Bronowicki, JP; Carrat, F; Dorival, C; Guedj, J; Hézode, C; Khelifa-Mouri, F; Lada, O; Laouénan, C; Lapalus, M; Marcellin, P; Martinot-Peignoux, M; Mentré, F; Nicot, F; Peytavin, G; Serfaty, L; Zoulim, F	1
Furusyo, N; Hayashi, J; Hiramine, S; Mitsumoto, F; Murata, M; Ogawa, E; Shimizu, M; Takayama, K; Toyoda, K; Ura, K	1
Borgia, F; Borgia, G; Buonomo, AR; Castaldo, G; Gentile, I; Zappulo, E	1
Carrier, P; Chambaraud, T; Debette-Gratien, M; Essig, M; Jacques, J; Loustaud-Ratti, V; Rousseau, A; Sautereau, D; Vong, C	1
Borgia, G; Buonomo, AR; Gentile, I	1
Ballow, C; Battegay, M; Elgadi, M; Feifel, U; Fuhr, R; Girlich, B; Haschke, M; Kort, J; Lang, B; Li, Y; Sabo, JP; Schobelock, M	1
Bliss, S; Lazariu, V; McNutt, LA; Miller, C; Nasiri, M; Patel, N; Veve, M	1
Arenas, JI; Bárcena, R; Buti, M; Calleja, JL; Crespo, J; de la Revilla, J; Delgado, M; Fernández-Rodríguez, CM; Forns, X; Gea, F; Larrubia, JR; Navarro, JM; Pascasio, JM; Pérez-Álvarez, R; Planas, R; Romero-Gómez, M; Ruiz-Antorán, B; Solá, R; Sousa, JM	1
Andreone, P; Conti, F; Vitale, G	1
Aldámiz-Echevarria, T; Berenguer, J; Fernández-Rodríguez, A; García-Alvarez, M; García-Broncano, P; Jiménez-Sousa, MÁ; López, JC; Micheloud, D; Miralles, P; Pineda-Tenor, D; Resino, S	1
Asselah, T; Böcher, WO; Huang, Q; Li, Y; Mease, K; Nehmiz, G; Olson, S; Podila, L; Sane, RS; Steinmann, GG; Stern, JO; Taub, ME; Tweedie, D	1
Aloia, AL; Beard, MR; Bent, SJ; Black, S; Carr, JM; Chase, R; Eyre, NS; Gaeguta, A; Guo, Z; Howe, JA; Locarnini, S; Narayana, SK	1
Zeuzem, S	1
Stirnimann, G	1
Elgadi, M; Halabi, A; Huang, F; Lang, B; Moschetti, V; Petersen-Sylla, M; Yong, CL	1
Bremer, B; Calvaruso, V; Cloherty, G; Craxì, A; Haragh, A; Hunyady, B; Maasoumy, B; Makara, M; Manns, MP; Sarrazin, C; Susser, S; Vermehren, J; Wedemeyer, H	1
Firpi, RJ; Hilgenfeldt, E	1
Alachkar, N; Araz, F; Durand, CM; Gurakar, A; Latt, NL	1
Fangman, JJ; Guilfoyle, SM; Hyland, HA; Stockman, LJ; Vergeront, JM; Westergaard, RP	1
Dultz, G; Welzel, TM; Zeuzem, S	1
Ballow, C; Battegay, M; Chan, TS; Cooper, C; Girlich, B; Haschke, M; Kashuba, AD; Kort, J; Lang, B; Li, Y; O'Brien, D; Sabo, JP; Seibert, E; Ting, N; Tweedie, D; Zhang, W	1
Cohen, D; Collins, C; Dekhtyar, T; Gaultier, I; Hopkins, T; Irvin, M; Kempf, D; Lu, L; McDaniel, K; Menon, R; Middleton, T; Molla, A; Ng, T; Or, YS; Pilot-Matias, T; Pithawalla, R; Reisch, T; Tripathi, R	1
Beyer, J; Campbell, A; Collins, C; DeGoey, D; Kati, W; Koev, G; Krishnan, P; Mistry, N; Molla, A; Pilot-Matias, T; Reisch, T; Setze, C; Williams, L; Xie, W	1
Agarwal, K; Barnabas, A	1
Gutierrez, J; Martin, P; Trivella, JP	1
Gerlei, Z; Gervain, J; Horváth, G; Hunyady, B; Lengyel, G; Makara, M; Pár, A; Rókusz, L; Szalay, F; Telegdy, L; Tornai, I; Werling, K	1
Awni, W; Badri, P; Bernstein, B; Coakley, E; Cohen, D; Ding, B; Dutta, S; Menon, R; Podsadecki, T	1
Kanda, T; Omata, M; Yokosuka, O	1
Arena, U; Boldrini, B; Corti, G; Laffi, G; Marra, F; Milani, S; Montalto, P; Monti, M; Piluso, A; Salomoni, E; Stasi, C; Zignego, AL	1
Akker, Dv; Berry, SM; Broglio, KR; Daar, ES; Detry, MA; Kalsekar, A; Le, T; Lewis, RJ; Quintana, M; Spellberg, B; Yuan, Y	1
Harris, M; Igloi, Z; Kazlauskas, A; Macdonald, A; Mankouri, J; Saksela, K	1
Tornai, I	1
Campagna, D; Demma, S	1
Andreone, P; Gamal, N	1
Ianna, EA; Jones, TL; Reeves, GE; Tran, HA	1
Alshuth, U; Böker, K; Buggisch, P; Christensen, S; Hofmann, WP; Hüppe, D; Mauss, S; Pfeiffer-Vornkahl, H; Schott, E	1
Cheli, S; Clementi, E; Falvella, FS; Landonio, S; Lombardi, A; Magni, C; Mazzali, C; Mondelli, MU; Rizzardini, G	1
Abdi, AM; Allegra, S; Baiett, L; Boglione, L; D'Avolio, A; De Nicolò, A; Di Perri, G	1
Badri, PS; Dutta, S; King, JR; McGovern, BH; Menon, RM; Polepally, AR	1
Iwasa, T; Kinoshita, K; Nakamura, K; Takase, A	1
Cheng, PN; Hsu, SJ; Huang, CF; Lai, HC; Liu, CJ; Lo, CC; Mo, LR; Peng, CY; Su, CW; Su, WW; Tsai, WL; Tseng, KC; Wang, CH; Yang, CC; Yu, ML	1
Agostini, H; Alric, L; Antonini, TM; Botta-Fridlund, D; Calmus, Y; Coilly, A; De Ledinghen, V; Debette-Gratien, M; Duclos-Vallée, JC; Dumortier, J; Durand, F; Duvoux, C; Giostra, E; Guillaud, O; Latournerie, M; Lebray, P; Leroy, V; Moreno, C; Pageaux, GP; Radenne, S; Roche, B; Samuel, D; Saouli, AC	1
Antinori, S; Calvi, E; Milazzo, L; Regalia, E; Sollima, S; Torre, A	1
Kilvert, L; Lee, SS; Liu, H; Trepanier, J	1
Bani-Sadr, F; Dabis, F; Gilbert, C; Loko, MA; Morlat, P; Neau, D; Rosenthal, E; Salmon, D; Simon, A; Valantin, MA; Wittkop, L	1
Burger, DM; Claassen, MA; de Winter, BC; Hullegie, SJ; Koopmans, PP; Posthouwer, D; Rijnders, BJ	1
Abe, H; Aikata, H; Chayama, K; Ellis, JD; Hayes, CN; Hiraga, N; Imamura, M; Ishida, Y; Kan, H; Miyaki, E; Tateno, C; Tsuge, M; Uchida, T; Yoshimi, S	1
Gonzalez, YS; Huber, C; Juday, T; Saab, S; Wang, A	1
Beyer, J; Burroughs, M; Chayama, K; Collins, C; Krishnan, P; Kumada, H; Pilot-Matias, T; Redman, R; Reisch, T; Rodrigues, L; Schnell, G; Setze, C; Tripathi, R; Zhang, X	1
Asselah, T; Baum, P; Böcher, WO; Bourlière, M; Bronowicki, JP; Buti, M; Gallivan, JP; Gane, EJ; Lohse, AW; Mensa, FJ; Müllhaupt, B; Roberts, SK; Schuchmann, M; Soriano, V; Stern, JO; Voss, F; Zeuzem, S	1
Aichelburg, MC; Grabmeier-Pfistershammer, K; Mandorfer, M; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Schwabl, P; Steiner, S; Trauner, M	1
Arends, JE; Bierman, WF; Claassen, MA; Hullegie, SJ; Koopmans, PP; Lauw, FN; Leyten, EM; Newsum, AM; Posthouwer, D; Richter, C; Rijnders, BJ; van den Berk, GE; van der Meer, JT; van Eeden, A	1
Awni, W; Dutta, S; Khatri, A; Menon, R; Podsadecki, T; Trinh, R; Wang, H	1
Brennan, BJ; Eng, S; Gane, EJ; Hassanein, T; Kupcova, V; Le Pogam, S; Mazur, W; Morcos, PN; Rouzier, R; Scalori, A; Stedman, CA; Thommes, J; Voulgari, A	1
Cattaneo, D; Clementi, E; Gervasoni, C; Milazzo, L; Riva, A	1
Antonov, K; Atanasova, E; Boyanova, Y; Jelev, D; Krastev, Z; Mateva, L; Petkova, T; Tomov, B; Zheleva, N	1
Black, S; Chang, W; Hayashi, N; Hirano, T; Howe, AY; Kumada, H; Ludmerer, SW; Nakamura, K; Nickle, D; Takase, A; Tanaka, Y	1
Abunimeh, M; Bennett, M; Bernstein, DE; Cohen, DE; Cohen, E; Khatri, A; Lawitz, E; Mantry, PS; Pockros, PJ; Podsadecki, T; Reddy, KR; Shulman, NS; Sulkowski, MS; Wang, D	1
Awni, WM; Beck, D; Dutta, S; Khatri, A; Liu, W; Menon, RM; Mensing, S; Polepally, AR	1
Alshuth, U; Buggisch, P; Galle, PR; Grimm, D; Hueppe, D; Mauss, S; Pfeiffer-Vornkahl, H; Zimmermann, T	1
Cattaneo, D; D'Avolio, A; Gervasoni, C; Micheli, V; Milazzo, L; Sollima, S	1
Brainard, DM; Gane, EJ; Hyland, RH; McHutchison, JG; Schwabe, C; Stamm, LM; Stedman, CA; Svarovskaia, E; Yang, Y	1
Berry, K; Beste, LA; Chang, MF; Green, PK; Ioannou, GN; Lowy, E; Su, F; Tsui, JI	1
Bednasz, CJ; Difrancesco, R; Hagler, CE; Morse, GD; Ocque, AJ; Talal, AH; Woolwine-Cunningham, Y	1
Awni, WM; Badri, PS; Coakley, EP; Ding, B; Dutta, S; Menon, RM; Parikh, A	1
Tanaka, Y	1
Bryce, CL; Chidi, AP; Donohue, JM; Fine, MJ; Landsittel, DP; Myaskovsky, L; Rogal, SS; Smith, KJ; Switzer, GE; Tsung, A	1
Aguilar, H; Asatryan, A; Gane, E; Hassanein, T; Kort, J; Kwo, PY; Lalezari, J; Lin, CW; Liu, R; Maliakkal, B; Mensa, FJ; Ng, TI; Poordad, F; Wang, S; Wyles, DL	1
Antoniazzi, S; Bolis, M; Carnovale, C; Clementi, E; Gentili, M; Landonio, S; Magni, C; Niero, F; Radice, S	1
Abu Freha, N; Ben Yakov, G; Dizingof, V; Etzion, O; Fich, A; Monitin, S; Montano, D; Mushkalo, A; Shwarts, D; Sikuler, E; Takchick, A; Zilberman, D	1
Abonyi, M; Csefkó, K; Gervain, J; Haragh, A; Horváth, G; Hunyady, B; Jancsik, V; Makara, M; Makkai, E; Müller, Z; Ribiczey, P; Sipos, B; Szabó, O; Szalay, F; Szentgyörgyi, L; Tornai, I; Újhelyi, E; Varga, M; Weisz, G	1
Canini, L; Guedj, J; Perelson, AS	1
Srinivas, NR	1
Marshall, G	1
Awni, WM; Dutta, S; Eckert, D; Khatri, A; Menon, RM; Mensing, S; Podsadecki, TJ; Polepally, AR; Sharma, S	1
Anthony, DD; Bonomo, RA; Chandar, AK; Compan, A; Davitkov, P; Falck-Ytter, Y; Gideon, C; Hirsch, A; Silveira, MG; Smith, S	1
Ashimkhanova, A; Kaliaskarova, K; Yesmembetov, K	1
Carrero, A; Cervantes, M; Cifuentes, C; Cruceta, A; de Lazzari, E; Deig, E; Gómez-Sirvent, JL; Guardiola, JM; Jou, A; Laguno, M; López-Calvo, S; Mallolas, J; Martínez-Rebollar, M; Montes, ML; Murillas, J; Navarro, J; Pineda, JA; Ruiz-Mesa, JD; Tapiz, A; Van den Eynde, E; Veloso, S; Von Wichmann, MA	1
Alonso, A; Franco, A; Gentil, MA; González-Corvillo, C; Hernández-Marrero, D; Jiménez-Martín, C; Lauzurica, LR; Perelló, M; Sánchez-Fructuoso, A; Zarraga, S	1
Yu, ML	1
Abad, S; Albalate, M; de Sequera, P; Hernández, E; López-Gómez, JM; Macías, N; Mérida, E; Milla, M; Vega, A	1
Backus, LI; Belperio, PS; Bhattacharya, D; Goetz, MB; Loomis, TP; Mole, LA; Shahoumian, TA	1
Lim, SG	1
King, JR; Menon, RM	1
Arasappan, A; Bogen, S; Girijavallabhan, V; Njoroge, FG; Padilla, A; Pan, W; Ruan, S; Saksena, AK	1
Pár, A; Pár, G	1
Gonzàlez-Candelas, F; López-Labrador, FX; Moya, A	1
Curry, S; Qiu, P; Tong, X	1
Allen, TM; Berical, A; Berlin, AM; Bihl, F; Birch, C; Birren, BW; Carlson, J; Cerny, A; Chung, RT; Daar, ES; Donfield, SM; Edlin, BR; Fleckenstein, JF; Galagan, JE; Gomperts, ED; Heckerman, D; Henn, MR; Jacobson, IM; Kim, AY; Kleyman, M; Kodira, C; Koehrsen, M; Kuntzen, T; Lake-Bakaar, GV; Lauer, GM; Ledlie, T; Lee, B; Lennon, N; Liu, Z; Madey, MA; Marion, T; McMahon, CM; Nusbaum, C; Park, VM; Reyor, LL; Roberts, AD; Rosen, HR; Schneidewind, A; Schulze Zur Wiesch, J; Spengler, U; Talal, AH; Timm, J; Walker, BD; Xing, Y; Young, SK	1
Manns, MP; Mederacke, I; Wedemeyer, H	1
Berman, K; Kwo, PY	1
Domingues, FS; Herrmann, E; Hughes, E; Karey, U; Ralston, R; Sarrazin, C; Susser, S; Tong, X; Wang, Y; Welsch, C; Zettler, M; Zeuzem, S	1
Nelson, DR	2
Blackman, M; Madison, V; Njoroge, FG; Velazquez, F; Venkatraman, S; Wu, W	1
Back, D; Khoo, S; Seden, K	1
Deshpande, M; Huang, M; Miller, MD; Mo, H; Murray, B; Qi, X; Rhodes, G; Sun, SC; Wang, K; Wang, Y; Yang, C	1
Opar, A	1
Rodríguez-Torres, M	1
Deutsch, M; Papatheodoridis, GV	1
Poordad, F	1
Benhamou, Y; Berg, T; Boecher, WO; Bonacini, M; Bourlière, M; Calleja, JL; Kukolj, G; Manns, MP; Pol, S; Scherer, J; Steinmann, G; Stern, JO; Trepo, C; White, PW; Wright, D; Yong, CL	1
Fried, MW	1
Pawlotsky, JM	2
Goudreau, N; Hucke, O; Lemke, CT; Llinàs-Brunet, M; Thibeault, D; White, PW; Zhao, S	1
Pockros, PJ	1
Aronsohn, A; Jensen, D	1
Gravitz, L	1
Schlütter, J	1
Wood, NJ	1
Bukh, J; Ghanem, L; Gottwein, JM; Jensen, TB; Scheel, TK	1
Charlton, M	1
Sheridan, C	1
Bradford, W; Forestier, N; Guyader, D; Larrey, D; Lim, S; Marcellin, P; Patat, A; Porter, S; Qin, X; Rouzier, R; Seiwert, SD; Smith, PF; Zeuzem, S	1
Wapner, J	1
Kwo, PY; Zhao, R	1
Ciesek, S; Manns, MP; von Hahn, T	1
Bruno, R; Fagiuoli, S; Sacchi, P	1
Forestier, N; Füller, C; Grigorian, N; Perner, D; Sarrazin, C; Susser, S; Vermehren, J; Welker, MW; Zeuzem, S	1
Razonable, RR	1
Goossens, N; Negro, F	1
Mutimer, DJ; Rowe, IA	1
Nehra, V; Rizza, SA; Talwani, R; Temesgen, Z	1
Carpio-Pedroza, JC; Cazares, F; Cruz-Rivera, MY; Escobar-Gutiérrez, A; Fonseca-Coronado, S; Rivera-Osorio, P; Ruíz-Pacheco, JA; Ruiz-Tovar, K; Vaughan, G; Vazquez-Pichardo, M	1
Butt, AA; Kanwal, F	1
Hofmann, WP; Zeuzem, S	1
Dignass, A; Faiss, S; Galle, P; Layer, P; Lerch, M; Malfertheiner, P; Wehrmann, T; Zeuzem, S	1
Forestier, N; Hughes, E; Karey, U; Lange, CM; Ralston, R; Sarrazin, C; Susser, S; Tong, X; Vermehren, J; Zeuzem, S	1
Reinke, T	1
Hou, T; Li, Y; Mao, X; Yu, H; Zhang, L; Zhu, J	1
Cheiab, B; Ioniţă-Radu, F; Raşcanu, A	1
Gervain, J; Horváth, G; Hunyady, B; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I; Ujhelyi, E	1
Alkhouri, N; Zein, NN	1
Klibanov, OM; Olin, JL; Smith, LS; Vickery, SB; Williams, SH	1
Hong, BA; Kerr, T; North, CS	1
Ambrogelly, A; Brennan, T; Gloor, G; Huisman, G; Lalonde, J; Lekhal, A; Li, T; Liang, J; Mijts, B; Muley, S; Newman, L; Tobin, M; Wong, G; Zaks, A; Zhang, X	1
Bronte, F; Bruno, R; Cammà, C; Capursi, V; Cicchetti, A; Colombo, GL; Craxì, A; Di Marco, V; Enea, M; Gasbarrini, A; Petta, S	1
Cacoub, P; Picard, O	1
Venkatraman, S	1
Butterton, J; Feng, HP; Gupta, S; Hulskotte, E; O'Mara, E; van Zutven, M; Wagner, J; Xuan, F	1
Kuehn, BM	1
Albrecht, JK; Bacon, BR; Boparai, N; Brass, CA; Bronowicki, JP; Burroughs, MH; Gordon, SC; Goteti, VS; Jacobson, IM; Molony, C; Morgan, TR; Pedicone, LD; Poordad, F; Poynard, T; Sings, HL; Sniukiene, V; Sulkowski, MS; Zeuzem, S	1
Perelson, AS; Ribeiro, RM; Rong, L	1
Assis, DN; Lim, JK	1
Ali, A; Aydin, C; Cao, H; Deveau, LM; Huang, W; Newton, A; Ozen, A; Petropoulos, CJ; Romano, KP; Schiffer, CA; Silver, C; Soumana, D	1
Pascale, A; Serfaty, L	1
Barry, M; Bergin, C; Kieran, J; Norris, S; O'Leary, A; Schmitz, S; Walsh, C	1
Barreiro, P; Fernández-Montero, JV; Labarga, P; Soriano, V; Vispo, E	1
Bárcena, R; Casado, JL; Del Campo, S; Dronda, F; Mateos, ML; Montes, M; Moreno, A; Moreno, S; Pérez-Elías, MJ; Quereda, C; Rodríguez-Sagrado, MA	1
Albrecht, JK; Bacon, B; Brass, CA; Bruno, S; Burroughs, MH; Esteban, R; Goodman, Z; Gottesdiener, K; Nyberg, LM; Pedicone, LD; Poordad, F; Tanno, H; Thompson, S; Vierling, JM	1
Lemon, M	1
Tillmann, HL	1
Allen, T; Ansari, IU; Barin, B; Berical, A; Stock, PG; Striker, R	1
Muir, AJ	1
Belouzard, S; Biot, C; Calland, N; Cocquerel, L; Descamps, V; Douam, F; Dubuisson, J; Duverlie, G; Fénéant, L; François, C; Guérardel, Y; Helle, F; Lavillette, D; Vausselin, T; Wahid, A; Wychowski, C	1
Aronsohn, A; Jensen, D; Muir, AJ; Swan, T	1
Cornberg, M; Kirschner, J; Maasoumy, B; Manns, MP; Markova, AA; Mix, C; Port, K; Rogalska-Taranta, M; Serrano, BC; Sollik, L; Wedemeyer, H	1
Sulkowski, MS	2
Cottrell, KM; Court, JJ; Courtney, LF; Deininger, DD; Farmer, LJ; Gates, CA; Harbeson, SL; Kim, JL; Lin, C; Lin, K; Luong, YP; Maxwell, JP; Murcko, MA; Perni, RB; Pitlik, J; Rao, BG; Schairer, WC; Thomson, JA; Tung, RD; Van Drie, JH; Wilson, K	1
Cutler, D; Forestier, N; Gupta, SK; Hussain, M; Larrey, D; Rouzier, R; Sarrazin, C; Shah, A; Wagner, F; Zeuzem, S; Zhang, J	1
Iino, S	1
Chen, KX; Njoroge, FG; Piwinski, JJ; Shih, NY	1
Kozal, MJ; Liu-Young, G	1
Kimura, J; Matsuura, Y; Miyamura, T; Mori, A; Seki, M; Yamada, K; Yuasa, S	1

Reviews

85 review(s) available for proline and Hepatitis C

Article	Year
Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials. Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:4 Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides	2020
Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics. Journal of viral hepatitis, 2020, Volume: 27, Issue:8 Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Child; Child, Preschool; Cyclopropanes; Disease Eradication; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Pediatrics; Proline; Pyrrolidines; Quality of Life; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; World Health Organization	2020
Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2020, Volume: 18, Issue:11 Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides	2020
Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy. Drug design, development and therapy, 2020, Volume: 14 Topics: Antiviral Agents; Cyclopropanes; Enzyme Inhibitors; Genotype; Hepacivirus; Hepatitis C; Humans; Isoindoles; Lactams, Macrocyclic; Microbial Sensitivity Tests; Proline; Serine Proteases; Sulfonamides; Viral Nonstructural Proteins	2020
Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2 Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea	2022
Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis. Journal of viral hepatitis, 2017, Volume: 24, Issue:11 Topics: Anilides; Antiviral Agents; Carbamates; Comorbidity; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load	2017
Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C. Expert opinion on drug metabolism & toxicology, 2017, Volume: 13, Issue:9 Topics: Aminoisobutyric Acids; Animals; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Tablets; Treatment Outcome	2017
Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C. The Annals of pharmacotherapy, 2018, Volume: 52, Issue:4 Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides	2018
Cutaneous eruptions by new therapies against hepatitis C virus infection. Not as common as we presumed. International journal of dermatology, 2018, Volume: 57, Issue:4 Topics: 2-Naphthylamine; Adrenal Cortex Hormones; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Eruptions; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Histamine Antagonists; Humans; Incidence; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine	2018
Glecaprevir + pibrentasvir for treatment of hepatitis C. Expert opinion on pharmacotherapy, 2018, Volume: 19, Issue:4 Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Half-Life; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Proline; Protease Inhibitors; Pyrrolidines; Quinoxalines; Sulfonamides; Treatment Outcome	2018
Sofosbuvir, velpatasvir and voxilaprevir combination therapy for treating patients with hepatitis C virus infection. Drugs of today (Barcelona, Spain : 1998), 2018, Volume: 54, Issue:4 Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Outcome	2018
Sofosbuvir/velpatasvir/voxilaprevir: a highly effective option for retreatment of hepatitis C in difficult-to-treat patients. Antiviral therapy, 2019, Volume: 24, Issue:1 Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides	2019
Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure. Clinical and molecular hepatology, 2019, Volume: 25, Issue:4 Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Proline; Quinoxalines; Randomized Controlled Trials as Topic; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure	2019
[Boceprevir and telaprevir: clinical efficacy, safety and drug-drug interactions]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2012, Volume: 57, Issue:9-10 Topics: Antiviral Agents; Drug Interactions; Hepacivirus; Hepatitis C; Humans; Oligopeptides; Proline	2012
HCV RNA viral load assessments in the era of direct-acting antivirals. The American journal of gastroenterology, 2013, Volume: 108, Issue:4 Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Oligopeptides; Proline; Protease Inhibitors; Real-Time Polymerase Chain Reaction; RNA, Viral; Viral Load	2013
Pretransplant and posttransplant treatment of hepatitis C virus infection with protease inhibitors. Current opinion in organ transplantation, 2013, Volume: 18, Issue:3 Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Oligopeptides; Postoperative Care; Preoperative Care; Proline; Protease Inhibitors	2013
Psychiatric treatment considerations with direct acting antivirals in hepatitis C. BMC gastroenterology, 2013, May-14, Volume: 13 Topics: Antiviral Agents; Contraindications; Drug Interactions; Hepatitis C; Humans; Medication Adherence; Mental Disorders; Oligopeptides; Proline; Psychotropic Drugs	2013
Optimizing DAA management in daily practice. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Sep-30, Volume: 45 Suppl 5 Topics: Antiviral Agents; Checklist; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Medication Adherence; Oligopeptides; Patient Education as Topic; Polyethylene Glycols; Proline; Ribavirin	2013
Optimizing treatment in HIV/HCV coinfection. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Sep-30, Volume: 45 Suppl 5 Topics: Anti-Retroviral Agents; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Oligopeptides; Proline; Ribavirin	2013
Safety of direct antiviral agents in real life. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Sep-30, Volume: 45 Suppl 5 Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Oligopeptides; Proline; Protease Inhibitors	2013
Hepatitis C direct-acting antiviral agents: changing the paradigm of hepatitis C treatment in HIV-infected patients. Journal of clinical gastroenterology, 2014, Volume: 48, Issue:2 Topics: Aminoisobutyric Acids; Antiviral Agents; Coinfection; Hepatitis C; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Interferons; Leucine; Oligopeptides; Proline; Protease Inhibitors; Quinolines; Simeprevir; Sulfonamides; Thiazoles; Viral Nonstructural Proteins	2014
Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: resolved and unresolved issues. Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:1 Topics: Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Interferon-alpha; Liver Neoplasms; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Virus Activation	2014
[Hepatitis C virus: 25 years-old, the end?]. Medecine sciences : M/S, 2013, Volume: 29, Issue:11 Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Proline; Protease Inhibitors; Ribavirin	2013
How to optimize current therapy of HCV genotype 1 infection with boceprevir. Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Oligopeptides; Proline; Risk Assessment; Treatment Outcome	2014
Management of HCV patients with cirrhosis with direct acting antivirals. Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1 Topics: Algorithms; Aminoisobutyric Acids; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Leucine; Liver Cirrhosis; Oligopeptides; Proline; Quinolines; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Time Factors; Uridine Monophosphate	2014
Management of HCV transplant patients with triple therapy. Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1 Topics: Antiviral Agents; Disease Management; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Oligopeptides; Proline; Secondary Prevention; Treatment Outcome	2014
Treating HCV in HIV 2013: on the cusp of change. Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1 Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Leucine; Oligopeptides; Proline; Pyrrolidines; Quinolines; Sofosbuvir; Thiazoles; Treatment Outcome; Uridine Monophosphate; Valine	2014
Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir. Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1 Topics: Aminoisobutyric Acids; Antiviral Agents; Clinical Trials as Topic; Drug Approval; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Leucine; Oligopeptides; Proline; Quinolines; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Time Factors; Uridine Monophosphate	2014
HCV direct-acting antiviral agents: the best interferon-free combinations. Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1 Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials as Topic; Disease Eradication; Drug Discovery; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Leucine; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Pyrrolidines; Quinolines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Virus Replication	2014
New antiviral agents for the treatment of hepatitis C: ABT-450. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:5 Topics: Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Viral Nonstructural Proteins	2014
Importance of HCV genotype 1 subtypes for drug resistance and response to therapy. Journal of viral hepatitis, 2014, Volume: 21, Issue:4 Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Species Specificity; Treatment Outcome	2014
Hepatitis C treatment: an incipient therapeutic revolution. Trends in molecular medicine, 2014, Volume: 20, Issue:6 Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Molecular Targeted Therapy; Oligopeptides; Proline; Protease Inhibitors; Sofosbuvir; Uridine Monophosphate	2014
The cost-effectiveness of boceprevir for hepatitis C. Expert review of pharmacoeconomics & outcomes research, 2014, Volume: 14, Issue:3 Topics: Antiviral Agents; Cost-Benefit Analysis; Economics, Pharmaceutical; Hepatitis C; Humans; Proline	2014
Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage? European journal of clinical pharmacology, 2014, Volume: 70, Issue:7 Topics: Animals; Antiviral Agents; Arrhythmias, Cardiac; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Food-Drug Interactions; Hepacivirus; Hepatitis C; Humans; Oligopeptides; Proline; Risk Assessment; Risk Factors; Serine Proteinase Inhibitors	2014
Response-guided therapy in patients with genotype 1 hepatitis C virus: current status and future prospects. Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:8 Topics: Antiviral Agents; Clinical Trials as Topic; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Treatment Outcome; Viral Load; Virus Replication	2014
Hepatitis C in HIV-infected patients: impact of direct-acting antivirals. Drugs, 2014, Volume: 74, Issue:9 Topics: Antiviral Agents; Hepacivirus; Hepatitis C; HIV Infections; Humans; Oligopeptides; Proline	2014
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world? Expert review of anti-infective therapy, 2014, Volume: 12, Issue:7 Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials as Topic; Cyclopropanes; Disease Eradication; Drug Combinations; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine	2014
Emerging therapeutic options for the management of hepatitis C infection. World journal of gastroenterology, 2014, Jun-21, Volume: 20, Issue:23 Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Host-Pathogen Interactions; Humans; Molecular Targeted Therapy; Oligopeptides; Proline; Protease Inhibitors; RNA-Dependent RNA Polymerase; Treatment Outcome; Viral Nonstructural Proteins; Virus Replication	2014
ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection. Current medicinal chemistry, 2014, Volume: 21, Issue:28 Topics: Cyclopropanes; Drug Resistance, Viral; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Protease Inhibitors; Sulfonamides; Treatment Outcome	2014
Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection. Expert review of anti-infective therapy, 2014, Volume: 12, Issue:9 Topics: Anilides; Animals; Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Proline; RNA, Viral; Valine; Viral Nonstructural Proteins	2014
Treating hepatitis C in the elderly: the future is near? Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:14 Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Medication Adherence; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin	2014
Decade in review-HCV: hepatitis C therapy-a fast and competitive race. Nature reviews. Gastroenterology & hepatology, 2014, Volume: 11, Issue:11 Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin	2014
Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:17 Topics: Anilides; Animals; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Proline; Ribavirin; Valine; Viral Nonstructural Proteins	2014
Hepatitis C management in post-transplant patients. Minerva gastroenterologica e dietologica, 2015, Volume: 61, Issue:1 Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fluorenes; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Pyrrolidines; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Valine; Viral Load	2015
Management of hepatitis C infection among patients with renal failure. Minerva gastroenterologica e dietologica, 2015, Volume: 61, Issue:1 Topics: Antiviral Agents; Global Health; Guidelines as Topic; Hepatitis C; Humans; Incidence; Italy; Kidney Failure, Chronic; Kidney Transplantation; Prevalence; Proline; Treatment Outcome	2015
Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors. Journal of hepatology, 2014, Volume: 61, Issue:1 Suppl Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Nucleic Acid Synthesis Inhibitors; Oligopeptides; Proline; Protease Inhibitors; Viral Nonstructural Proteins	2014
A 4-drug combination (Viekira Pak) for hepatitis C. The Medical letter on drugs and therapeutics, 2015, Feb-02, Volume: 57, Issue:1461 Topics: 2-Naphthylamine; Anilides; Animals; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Uracil; Valine	2015
Faldaprevir for the treatment of genotype-1 hepatitis C virus. Expert review of gastroenterology & hepatology, 2015, Volume: 9, Issue:3 Topics: Aminoisobutyric Acids; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Leucine; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Quinolines; Ribavirin; Thiazoles	2015
[Hepatitis C: diagnosis, anti-viral therapy, after-care. Hungarian consensus guideline]. Orvosi hetilap, 2015, Mar-01, Volume: 156, Issue:9 Topics: Antiviral Agents; Consensus; Disease Progression; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Hepatitis C; Humans; Hungary; Insurance Coverage; Insurance, Health; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Registries; Ribavirin; Treatment Outcome	2015
Faldaprevir for the treatment of hepatitis C. International journal of molecular sciences, 2015, Mar-04, Volume: 16, Issue:3 Topics: Aminoisobutyric Acids; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Leucine; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Thiazoles; Viral Nonstructural Proteins	2015
A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens. Journal of comparative effectiveness research, 2015, Volume: 4, Issue:2 Topics: Algorithms; Antiviral Agents; Bayes Theorem; Comparative Effectiveness Research; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Proline; Ribavirin; Treatment Outcome	2015
[Significance of hepatitis C virus baseline polymorphism during the antiviral therapy]. Orvosi hetilap, 2015, May-24, Volume: 156, Issue:21 Topics: Antiviral Agents; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Nucleic Acid Synthesis Inhibitors; Oligopeptides; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Proline; Protease Inhibitors; Ribavirin; Simeprevir; Sulfonamides; Viral Load; Viral Nonstructural Proteins; Virus Replication	2015
Faldaprevir for the treatment of hepatitis C. Drugs of today (Barcelona, Spain : 1998), 2015, Volume: 51, Issue:5 Topics: Aminoisobutyric Acids; Animals; Antiviral Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Discovery; Drug Interactions; Hepatitis C; Humans; Leucine; Molecular Structure; Oligopeptides; Proline; Quinolines; Thiazoles; Tissue Distribution; Treatment Outcome; Viral Nonstructural Proteins	2015
Working together to tackle HCV infection: ombitasvir/paritaprevir/ritonavir and dasabuvir combination. Drugs of today (Barcelona, Spain : 1998), 2015, Volume: 51, Issue:5 Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Molecular Structure; Proline; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine	2015
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy. Clinical pharmacokinetics, 2016, Volume: 55, Issue:3 Topics: Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Interactions; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Valine	2016
[Preclinical and clinical properties of vaniprevir (VANIHEP® Capsules 150 mg), a novel therapeutic agent for hepatitis C]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2015, Volume: 146, Issue:3 Topics: Antiviral Agents; Capsules; Clinical Trials as Topic; Cyclopropanes; Hepacivirus; Hepatitis C; Humans; Indoles; Isoindoles; Lactams, Macrocyclic; Leucine; Proline; Sulfonamides	2015
Technivie for HCV genotype 4 infection. The Medical letter on drugs and therapeutics, 2015, Nov-23, Volume: 57, Issue:1482 Topics: Anilides; Animals; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Randomized Controlled Trials as Topic; Ritonavir; Sulfonamides; Valine	2015
[Latest Treatment of Viral Hepatitis--Overcoming Hepatitis C and Reactivation of Hepatitis B]. Rinsho byori. The Japanese journal of clinical pathology, 2016, Volume: 64, Issue:2 Topics: Anilides; Antineoplastic Agents; Antiviral Agents; Biomarkers; Carbamates; Cyclopropanes; DNA, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis C; Humans; Imidazoles; Immunoassay; Immunosuppressive Agents; Interferons; Interleukins; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Ritonavir; Rituximab; Sensitivity and Specificity; Sulfonamides; Transfusion Reaction; Valine; Virus Activation	2016
Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens. Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:8 Topics: Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Interferons; Isoquinolines; Oligopeptides; Proline; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Time Factors; Valine; Viral Load	2017
HCV management in resource-constrained countries. Hepatology international, 2017, Volume: 11, Issue:3 Topics: Aminoisobutyric Acids; Antiviral Agents; Australia; Benzimidazoles; Carbamates; Continuity of Patient Care; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Drugs, Generic; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Risk Factors; Sofosbuvir; Sulfonamides; Valine	2017
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse. Clinical pharmacology in drug development, 2017, Volume: 6, Issue:2 Topics: 2-Naphthylamine; Anilides; Anti-Retroviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Protease Inhibitors; Ritonavir; Substance-Related Disorders; Sulfonamides; Uracil; Valine	2017
Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection. Current opinion in investigational drugs (London, England : 2000), 2009, Volume: 10, Issue:2 Topics: Animals; Capsules; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation, Preclinical; Hepacivirus; Hepatitis C; Humans; Molecular Structure; Proline; Serine Proteinase Inhibitors; Viral Nonstructural Proteins	2009
Boceprevir, an NS3 protease inhibitor of HCV. Clinics in liver disease, 2009, Volume: 13, Issue:3 Topics: Antiviral Agents; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Proline; Protease Inhibitors; Viral Nonstructural Proteins	2009
Boceprevir. Drugs in R&D, 2010, Volume: 10, Issue:3 Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Drugs, Investigational; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Microbial Sensitivity Tests; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins	2010
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients. Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31 Suppl 1 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin	2011
Boceprevir: a user's guide. Clinics in liver disease, 2011, Volume: 15, Issue:3 Topics: Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins	2011
Second-wave protease inhibitors: choosing an heir. Clinics in liver disease, 2011, Volume: 15, Issue:3 Topics: Aminoisobutyric Acids; Antiviral Agents; Carrier Proteins; Cyclopropanes; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Intracellular Signaling Peptides and Proteins; Isoindoles; Lactams; Lactams, Macrocyclic; Leucine; Oligopeptides; Proline; Protease Inhibitors; Quinolines; Simeprevir; Sulfonamides; Thiazoles; Viral Nonstructural Proteins	2011
Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clinic proceedings, 2011, Volume: 86, Issue:10 Topics: Acyclovir; Adenine; Amantadine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Foscarnet; Ganciclovir; Guanine; Hepatitis; Hepatitis B, Chronic; Hepatitis C; Herpesviridae Infections; HIV Infections; Humans; Influenza, Human; Interferons; Lamivudine; Nucleosides; Oligopeptides; Organophosphonates; Oseltamivir; Proline; Protease Inhibitors; Pyrimidinones; Ribavirin; Telbivudine; Thymidine; Valacyclovir; Valganciclovir; Valine; Virus Replication; Zanamivir	2011
Protease inhibitors for treatment of genotype 1 hepatitis C virus infection. BMJ (Clinical research ed.), 2011, Nov-10, Volume: 343 Topics: Cost-Benefit Analysis; Drug Interactions; Drug Monitoring; Genotype; Hepacivirus; Hepatitis C; Humans; Oligopeptides; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic	2011
Boceprevir. Drugs of today (Barcelona, Spain : 1998), 2011, Volume: 47, Issue:10 Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Drug Interactions; Hepatitis C; Humans; Proline; Viral Nonstructural Proteins	2011
Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Jan-01, Volume: 54, Issue:1 Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Oligopeptides; Proline; Ribavirin; Treatment Outcome	2012
Hepatitis C in 2011: A new standard of care and the race towards IFN-free therapy. Nature reviews. Gastroenterology & hepatology, 2011, Dec-20, Volume: 9, Issue:2 Topics: Antiviral Agents; Contraindications; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Randomized Controlled Trials as Topic; Recombinant Proteins; RNA, Viral; Standard of Care	2011
IL28B polymorphism -- predictive factor of HCV infected genotype 1 individuals to treatment response and management of therapy. Romanian journal of internal medicine = Revue roumaine de medecine interne, 2011, Volume: 49, Issue:2 Topics: Antiviral Agents; Biomarkers; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Predictive Value of Tests; Proline; Recombinant Proteins; Ribavirin; Risk Assessment; Sensitivity and Specificity; Treatment Outcome	2011
Protease inhibitors: silver bullets for chronic hepatitis C infection? Cleveland Clinic journal of medicine, 2012, Volume: 79, Issue:3 Topics: Antiviral Agents; Chronic Disease; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins	2012
Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C. Pharmacotherapy, 2012, Volume: 32, Issue:2 Topics: Clinical Trials as Topic; Hepatitis C; Humans; Proline; Protease Inhibitors; Treatment Outcome; Viral Nonstructural Proteins	2012
Hepatitis C and substance use: new treatments and novel approaches. Current opinion in psychiatry, 2012, Volume: 25, Issue:3 Topics: Antiviral Agents; Attitude of Health Personnel; Drug Therapy, Combination; Health Services Accessibility; Hepatitis C; Humans; Oligopeptides; Proline; Protease Inhibitors; Substance-Related Disorders	2012
Dermatological adverse effects during genotype-1 hepatitis C treatment with the protease inhibitors telaprevir and boceprevir. Patient management. Clinics and research in hepatology and gastroenterology, 2012, Volume: 36, Issue:5 Topics: Drug Eruptions; Genotype; Hepacivirus; Hepatitis C; Humans; Oligopeptides; Proline; Protease Inhibitors	2012
Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections. Trends in pharmacological sciences, 2012, Volume: 33, Issue:5 Topics: Animals; Antiviral Agents; Carrier Proteins; Drug Discovery; Hepatitis C; Humans; Intracellular Signaling Peptides and Proteins; Proline; Protease Inhibitors; Protein Conformation; Viral Nonstructural Proteins	2012
New pharmacotherapy for hepatitis C. Clinical pharmacology and therapeutics, 2012, Volume: 92, Issue:3 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Humans; Liver; Oligopeptides; Proline	2012
The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:2 Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Oligopeptides; Proline; Recurrence; Treatment Outcome	2013
IL28B in the era of direct-acting antivirals for hepatitis C. Journal of clinical gastroenterology, 2013, Volume: 47, Issue:3 Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Interleukins; Oligopeptides; Proline; Time Factors; Treatment Outcome	2013
Specific targeted antiviral therapy for hepatitis C. Current gastroenterology reports, 2007, Volume: 9, Issue:1 Topics: Antiviral Agents; Benzofurans; Clinical Trials as Topic; Cytidine; Hepatitis C; Humans; Prodrugs; Proline; Protease Inhibitors; RNA-Dependent RNA Polymerase	2007
[Drugs for hepatitis B and C infection]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Feb-28, Volume: 65 Suppl 2 Pt. 1 Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Lamivudine; Mutation; Oligopeptides; Organophosphonates; Proline; Ribavirin; Serine Proteinase Inhibitors	2007
Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Accounts of chemical research, 2008, Volume: 41, Issue:1 Topics: Animals; Clinical Trials, Phase I as Topic; Crystallography, X-Ray; Drug Design; Hepatitis C; Humans; Microbial Sensitivity Tests; Models, Molecular; Proline; Protease Inhibitors; Structure-Activity Relationship; Viral Nonstructural Proteins	2008
Hepatitis C protease and polymerase inhibitors in development. AIDS patient care and STDs, 2008, Volume: 22, Issue:6 Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Multicenter Studies as Topic; Oligopeptides; Proline; Protease Inhibitors; Pyrimidine Nucleosides; Randomized Controlled Trials as Topic	2008

Trials

65 trial(s) available for proline and Hepatitis C

Article	Year
Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus-1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub-study A5334s. British journal of clinical pharmacology, 2020, Volume: 86, Issue:1 Topics: 2-Naphthylamine; Acquired Immunodeficiency Syndrome; Adult; Anilides; Antiviral Agents; Coinfection; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV-1; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Raltegravir Potassium; Ritonavir; Sulfonamides; Uracil; Valine	2020
Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials. Journal of viral hepatitis, 2020, Volume: 27, Issue:5 Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carcinoma, Hepatocellular; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Neoplasms; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine	2020
Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial. BMC infectious diseases, 2020, Apr-03, Volume: 20, Issue:1 Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Protease Inhibitors; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine	2020
Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies. Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:10 Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Outcome	2020
Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2 Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea	2022
Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. Journal of the American Society of Nephrology : JASN, 2020, Volume: 31, Issue:11 Topics: Adult; Allografts; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Female; Glomerular Filtration Rate; Hepacivirus; Hepatitis C; Humans; Kidney; Kidney Transplantation; Lactams, Macrocyclic; Leucine; Male; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; RNA, Viral; Sulfonamides; Sustained Virologic Response	2020
TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir. The Journal of infectious diseases, 2017, 02-15, Volume: 215, Issue:4 Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Anti-Retroviral Agents; Body Mass Index; Carbamates; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Darunavir; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV-1; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Young Adult	2017
HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients. Journal of virological methods, 2017, Volume: 245 Topics: 2-Naphthylamine; Administration, Oral; Adult; Aged; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ribavirin; Ritonavir; RNA, Viral; Sensitivity and Specificity; Sulfonamides; Uracil; Viral Load	2017
Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients. Advances in therapy, 2017, Volume: 34, Issue:6 Topics: Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Japan; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Valine	2017
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. The New England journal of medicine, 2017, 06-01, Volume: 376, Issue:22 Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Protease Inhibitors; Quinoxalines; Sofosbuvir; Sulfonamides; Viral Nonstructural Proteins	2017
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. The Lancet. Infectious diseases, 2017, Volume: 17, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides	2017
Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III). Journal of viral hepatitis, 2018, Volume: 25, Issue:2 Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine	2018
Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor. Antiviral therapy, 2018, Volume: 23, Issue:4 Topics: Aminoisobutyric Acids; Cell Line; Cyclopropanes; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Protease Inhibitors; Quinoxalines; RNA, Viral; Sequence Analysis, RNA; Sulfonamides; Time Factors; Treatment Outcome; Viral Load; Virus Replication	2018
Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative Subjects. Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:3 Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Area Under Curve; Benzimidazoles; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepacivirus; Hepatitis C; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Renal Dialysis; Renal Insufficiency, Chronic; Sulfonamides	2018
Effect of ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on health-related quality of life for patients with hepatitis C. Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:8 Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Internationality; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Quality of Life; Regression Analysis; Ribavirin; Ritonavir; Severity of Illness Index; Sulfonamides; Sustained Virologic Response; Uracil; Valine	2018
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin. Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:9 Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Internationality; Lactams, Macrocyclic; Logistic Models; Macrocyclic Compounds; Male; Middle Aged; Multivariate Analysis; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine	2018
Pharmacokinetic Interaction between Faldaprevir and Cyclosporine or Tacrolimus in Healthy Volunteers: A Prospective, Open-Label, Fixed-Sequence, Crossover Study. Basic & clinical pharmacology & toxicology, 2018, Volume: 123, Issue:1 Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Area Under Curve; Cross-Over Studies; Cyclosporine; Drug Interactions; Female; Graft Rejection; Healthy Volunteers; Hepatitis C; Humans; Immunosuppressive Agents; Leucine; Liver Transplantation; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Quinolines; Secondary Prevention; Tacrolimus; Thiazoles; Young Adult	2018
Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice. HIV clinical trials, 2018, Volume: 19, Issue:1 Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine	2018
Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection. Journal of viral hepatitis, 2018, Volume: 25, Issue:10 Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Australia; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; England; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Intention to Treat Analysis; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; New Zealand; Proline; Prospective Studies; Ribavirin; Ritonavir; RNA, Viral; Safety; Sulfonamides; Treatment Outcome; Uracil; Valine	2018
Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. Journal of hepatology, 2019, Volume: 70, Issue:5 Topics: Adult; Aged; Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure	2019
Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole. The Journal of antimicrobial chemotherapy, 2013, Volume: 68, Issue:6 Topics: Adolescent; Adult; Anti-Ulcer Agents; Area Under Curve; Biotransformation; Cross-Over Studies; Drug Interactions; Female; Half-Life; Hepatitis C; Humans; Male; Middle Aged; Omeprazole; Patient Compliance; Proline; Protease Inhibitors; Young Adult	2013
Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2013, Volume: 19, Issue:7 Topics: Aged; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Interferon-alpha; Liver Failure; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome	2013
Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics. Antiviral research, 2013, Volume: 99, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carrier Proteins; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Isoindoles; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Protease Inhibitors; Sulfonamides; Viral Nonstructural Proteins; Young Adult	2013
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection. Gastroenterology, 2013, Volume: 145, Issue:4 Topics: Adult; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Epoxy Compounds; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Polyethylene Glycols; Proline; Pyridines; Recombinant Proteins; Ribavirin; Sulfonamides	2013
DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4. Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:1 Topics: Adult; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Polyethylene Glycols; Proline; Recombinant Proteins; Ritonavir; RNA, Viral; Sulfonamides	2015
SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:6 Topics: Adolescent; Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Carrier Proteins; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Leucine; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; RNA, Viral; Thiazoles; Viral Nonstructural Proteins; Young Adult	2014
The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology, 2014, Volume: 147, Issue:2 Topics: Adolescent; Adult; Aged; Amides; Antiviral Agents; Biomarkers; Carbamates; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Quinoxalines; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfonamides; Time Factors; Treatment Outcome; Young Adult	2014
Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study. Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:1 Topics: Adult; Aged; Cyclopropanes; Deoxycytidine; Electrocardiography; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides	2015
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology, 2014, Volume: 147, Issue:2 Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Biomarkers; Carbamates; Cyclopropanes; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Puerto Rico; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Time Factors; Treatment Outcome; United States; Uracil; Valine; Viral Load	2014
High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy. Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:2 Topics: Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; Statistics, Nonparametric; Viral Load	2015
Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:9 Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Kinetics; Male; Middle Aged; Models, Biological; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Treatment Outcome	2014
eGFR decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance? Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:1 Topics: Age Factors; Antiviral Agents; ErbB Receptors; Hepatitis C; Humans; Interferon-alpha; Kidney; Linear Models; Male; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin; Sex Factors	2015
Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Nov-15, Volume: 59, Issue:10 Topics: Adenine; Adult; Alkynes; Aminoisobutyric Acids; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Coinfection; Cyclopropanes; Darunavir; Drug Interactions; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Leucine; Male; Middle Aged; Oligopeptides; Organophosphonates; Proline; Protease Inhibitors; Quinolines; Ritonavir; Sulfonamides; Tenofovir; Thiazoles; Young Adult	2014
Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis. Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:1 Topics: Compassionate Use Trials; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; Spain	2015
Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients. The Journal of pharmacology and experimental therapeutics, 2014, Volume: 351, Issue:2 Topics: Aminoisobutyric Acids; Animals; Bilirubin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Double-Blind Method; Glucuronosyltransferase; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Hyperbilirubinemia; Leucine; Liver; Macaca mulatta; Multicenter Studies as Topic; Multidrug Resistance-Associated Protein 2; Oligopeptides; Proline; Quinolines; Randomized Controlled Trials as Topic; Rats; Thiazoles	2014
Pharmacokinetics, safety, and tolerability of faldaprevir in patients with renal impairment. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:1 Topics: Adult; Aged; Aminoisobutyric Acids; Biological Availability; Female; Half-Life; Hepatitis C; Humans; Leucine; Male; Middle Aged; Oligopeptides; Proline; Quinolines; Renal Insufficiency; Thiazoles	2015
Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: in vitro and in vivo correlation. Journal of clinical pharmacology, 2015, Volume: 55, Issue:4 Topics: Adolescent; Adult; Aminoisobutyric Acids; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Female; Healthy Volunteers; Hepatitis C; Humans; In Vitro Techniques; Isoenzymes; Leucine; Male; Microsomes, Liver; Midazolam; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Quinolines; Thiazoles; Warfarin; Young Adult	2015
In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:2 Topics: Antiviral Agents; Cyclopropanes; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Sulfonamides; Viral Nonstructural Proteins	2015
Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2015, Volume: 15, Issue:5 Topics: 2-Naphthylamine; Adolescent; Adult; Anilides; Antiviral Agents; Area Under Curve; Carbamates; Cyclopropanes; Cyclosporine; Drug Administration Schedule; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Sulfonamides; Tacrolimus; Uracil; Valine; Young Adult	2015
Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN cohort. Zeitschrift fur Gastroenterologie, 2015, Volume: 53, Issue:7 Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Evidence-Based Medicine; Female; Germany; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome	2015
Boceprevir and peginterferon α-2b plus ribavirin therapy of HCV genotype 3 relapsers: A pilot study. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2016, Volume: 48, Issue:3 Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Viral Load	2016
Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:2 Topics: Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genetics, Population; Hepacivirus; Hepatitis C; Humans; Japan; Lactams, Macrocyclic; Macrocyclic Compounds; Polymorphism, Genetic; Proline; Ritonavir; Sulfonamides; Treatment Failure; Valine; Viral Nonstructural Proteins	2016
ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection. PloS one, 2015, Volume: 10, Issue:12 Topics: Acrylates; Aminoisobutyric Acids; Anemia; Antiviral Agents; Benzimidazoles; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Leucine; Male; Middle Aged; Oligopeptides; Polymorphism, Single Nucleotide; Proline; Pyrophosphatases; Quinolines; Real-Time Polymerase Chain Reaction; Ribavirin; Thiazoles	2015
Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure. Wiener klinische Wochenschrift, 2016, Volume: 128, Issue:11-12 Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Treatment Outcome	2016
Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, Apr-15, Volume: 62, Issue:8 Topics: 2-Naphthylamine; Adolescent; Adult; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Sulfonamides; Uracil; Valine; Young Adult	2016
Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis. Hepatology international, 2016, Volume: 10, Issue:3 Topics: Antiviral Agents; Cyclopropanes; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Ritonavir; Sulfonamides; Treatment Failure	2016
HCV evolutionary genetics of SVR versus virologic failure assessed from the vaniprevir phase III registration trials. Antiviral research, 2016, Volume: 130 Topics: Amino Acid Substitution; Antiviral Agents; Codon; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Evolution, Molecular; Genotype; Hepacivirus; Hepatitis C; Humans; Indoles; Isoindoles; Lactams, Macrocyclic; Leucine; Mutation; Phylogeny; Proline; Sequence Analysis, DNA; Sulfonamides; Treatment Failure; Treatment Outcome	2016
Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease. Gastroenterology, 2016, Volume: 150, Issue:7 Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine	2016
Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies. Clinical pharmacokinetics, 2016, Volume: 55, Issue:9 Topics: Adolescent; Adult; Antiviral Agents; Biological Availability; Cyclopropanes; Drug Compounding; Drug Interactions; Drug Therapy, Combination; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Models, Biological; Proline; Protease Inhibitors; Ribavirin; Ritonavir; Sulfonamides; Young Adult	2016
Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1. Journal of gastrointestinal and liver diseases : JGLD, 2016, Volume: 25, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Germany; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Risk Factors; Smoking; Time Factors; Treatment Outcome; Viral Load; Young Adult	2016
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections. Gastroenterology, 2016, Volume: 151, Issue:3 Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; New Zealand; Proline; Protease Inhibitors; Quinoxalines; Serine Proteases; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins; Young Adult	2016
Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection. Therapeutic drug monitoring, 2016, Volume: 38, Issue:5 Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cyclosporine; Drug Dosage Calculations; Drug Therapy, Combination; Female; Hepatitis C; Humans; Immunosuppressive Agents; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Models, Biological; Proline; Ritonavir; Sulfonamides; Tacrolimus; Uracil; Valine; Young Adult	2016
High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. Gastroenterology, 2016, Volume: 151, Issue:4 Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Fibrosis; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response	2016
Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis C. PloS one, 2016, Volume: 11, Issue:10 Topics: Anemia; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Drug Tolerance; Female; Hepatitis C; Hospitalization; Humans; Interferon-alpha; Male; Middle Aged; Mood Disorders; Oligopeptides; Proline; Ribavirin; Severity of Illness Index; Treatment Outcome	2016
Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2016, Volume: 53 Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Prospective Studies; Recombinant Proteins; Retreatment; Ribavirin; Spain; Treatment Outcome; Viral Nonstructural Proteins	2016
Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay. Journal of virological methods, 2008, Volume: 153, Issue:2 Topics: Antiviral Agents; Base Pair Mismatch; Cross-Over Studies; DNA Mutational Analysis; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Mutation; Polyethylene Glycols; Polymerase Chain Reaction; Proline; Protease Inhibitors; Recombinant Proteins; Taq Polymerase; Treatment Outcome	2008
Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:6 Topics: Antiviral Agents; Double-Blind Method; Drug Resistance, Viral; Genotype; Hepatitis C; Humans; Models, Theoretical; Mutation; Oligopeptides; Phenotype; Proline; Protease Inhibitors; Viral Nonstructural Proteins	2009
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. Journal of hepatology, 2011, Volume: 54, Issue:6 Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carrier Proteins; Double-Blind Method; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Leucine; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Viral Load; Viral Nonstructural Proteins	2011
Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C. The Journal of infectious diseases, 2011, Aug-15, Volume: 204, Issue:4 Topics: Antiviral Agents; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Sulfonamides; Viral Nonstructural Proteins	2011
Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2011, Volume: 52, Issue:4 Topics: Antiviral Agents; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C; Humans; Longitudinal Studies; Mutation, Missense; Oligopeptides; Proline; RNA, Viral; Sequence Analysis, DNA; Viral Nonstructural Proteins	2011
Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology, 2012, Volume: 143, Issue:3 Topics: Adult; Antiviral Agents; Biomarkers; Canada; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Multivariate Analysis; Odds Ratio; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Proline; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; United States; Viral Load	2012
Safe coadministration of raltegravir-based HAART in HIV-infected patients with HCV-cirrhosis receiving triple therapy with telaprevir or boceprevir. Journal of acquired immune deficiency syndromes (1999), 2012, Nov-01, Volume: 61, Issue:3 Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Pyrrolidinones; Raltegravir Potassium; Recombinant Proteins; Ribavirin	2012
Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. Journal of hepatology, 2013, Volume: 58, Issue:3 Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral	2013
Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PloS one, 2013, Volume: 8, Issue:2 Topics: Antiviral Agents; Drug Therapy, Combination; Eligibility Determination; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Platelet Count; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Risk Assessment; Treatment Outcome	2013
SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology, 2007, Volume: 132, Issue:4 Topics: Administration, Oral; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Chromatography, Liquid; Cross-Over Studies; Drug Therapy, Combination; Europe; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Luminescent Measurements; Male; Middle Aged; Polymerase Chain Reaction; Proline; Recombinant Proteins; RNA, Viral; Treatment Outcome; Viral Load	2007

Other Studies

190 other study(ies) available for proline and Hepatitis C

Article	Year
High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence. The American journal of gastroenterology, 2021, 09-01, Volume: 116, Issue:9 Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Female; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Male; Medication Adherence; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Outcome	2021
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan. Scientific reports, 2021, 12-06, Volume: 11, Issue:1 Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Female; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Registries; Sulfonamides; Sustained Virologic Response; Taiwan; Treatment Outcome	2021
[A case of HCV genotype 3b with compensated stage cirrhosis who have two times treatment-experienced with the use of glecaprevir/pibrentasvir combined with sofosbuvir and ribavirin for 16 weeks]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2021, Dec-20, Volume: 29, Issue:12 Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome	2021
Trans-ancestral fine-mapping of MHC reveals key amino acids associated with spontaneous clearance of hepatitis C in HLA-DQβ1. American journal of human genetics, 2022, 02-03, Volume: 109, Issue:2 Topics: Acute Disease; Alleles; Amino Acid Substitution; Black People; Female; Gene Expression; Genome-Wide Association Study; Genotype; Hepacivirus; Hepatitis C; HLA-DQ beta-Chains; Host-Pathogen Interactions; Humans; Leucine; Male; Polymorphism, Single Nucleotide; Proline; Protein Isoforms; Remission, Spontaneous; White People	2022
Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis. Therapeutic drug monitoring, 2022, 06-01, Volume: 44, Issue:3 Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Organ Transplantation; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine	2022
Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection. Hepatology (Baltimore, Md.), 2022, Volume: 76, Issue:2 Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Child; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome	2022
Soluble inflammatory mediators identify HCV patients who may be cured with four weeks of antiviral treatment. Journal of viral hepatitis, 2022, Volume: 29, Issue:6 Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Inflammation Mediators; Proline; Quinoxalines	2022
hsa-miR-17-5p: A Possible Predictor of Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ± Ribavirin Therapy Efficacy in Hepatitis C Infection. Current microbiology, 2022, May-07, Volume: 79, Issue:6 Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; MicroRNAs; Proline; Ribavirin; Ritonavir; RNA, Messenger; Sulfonamides; Toll-Like Receptor 2; Treatment Outcome; Uracil; Valine	2022
Gadoxetic acid-enhanced magnetic resonance imaging predicts hyperbilirubinemia induced by glecaprevir during hepatitis C virus treatment. Scientific reports, 2022, 05-12, Volume: 12, Issue:1 Topics: Aminoisobutyric Acids; Bilirubin; Cyclopropanes; Gadolinium DTPA; Hepacivirus; Hepatitis C; Humans; Hyperbilirubinemia; Lactams, Macrocyclic; Leucine; Magnetic Resonance Imaging; Proline; Quinoxalines; Sulfonamides	2022
Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C. Journal of the Formosan Medical Association = Taiwan yi zhi, 2022, Volume: 121, Issue:11 Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzopyrans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Lipids; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sugars; Sulfonamides; Treatment Outcome	2022
Efficacy and Safety of Ombitasvir/Paritaprevir/ Ritonavir + Dasabuvir ± Ribavirin Combinations in Patients with Genotype 1 Hepatitis C and Inherited Bleeding Disorders. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2022, Volume: 33, Issue:5 Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Child; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine	2022
High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use. The Journal of infection, 2022, Volume: 85, Issue:3 Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Sulfonamides; Treatment Outcome	2022
Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry. Journal of gastroenterology and hepatology, 2022, Volume: 37, Issue:8 Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Registries; Sofosbuvir; Sulfonamides; Treatment Outcome	2022
High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use: Some issues. The Journal of infection, 2022, Volume: 85, Issue:4 Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides	2022
Successful nasoenteric administration of glecaprevir/pibrentasvir for donor-derived hepatitis C in two young adult heart transplant recipients at a pediatric transplant center. Pediatric transplantation, 2022, Volume: 26, Issue:7 Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Child; Cyclopropanes; Genotype; Heart Transplantation; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Young Adult	2022
Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting. PloS one, 2022, Volume: 17, Issue:8 Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Retrospective Studies; Sulfonamides	2022
Characterisation of a Hepatitis C Virus Subtype 2a Cluster in Scottish PWID with a Suboptimal Response to Glecaprevir/Pibrentasvir Treatment. Viruses, 2022, 07-29, Volume: 14, Issue:8 Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Phylogeny; Proline; Pyrrolidines; Quinoxalines; Scotland; Substance Abuse, Intravenous; Sulfonamides	2022
Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2019, Volume: 30, Issue:8 Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cyclosporine; Female; Hepacivirus; Hepatitis C; Humans; Kidney Transplantation; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Postoperative Complications; Proline; Ritonavir; Sulfonamides; Sustained Virologic Response; Tacrolimus; Uracil; Valine	2019
Efficacy and Safety of Glecaprevir/pibrentasvir in a Patient With HCV-Induced Porphyria Cutanea Tarda Receiving Vedolizumab for Crohn´s Disease. Journal of Crohn's & colitis, 2020, May-21, Volume: 14, Issue:4 Topics: Aminoisobutyric Acids; Antibodies, Monoclonal, Humanized; Benzimidazoles; Crohn Disease; Cyclopropanes; Gastrointestinal Agents; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Porphyria Cutanea Tarda; Proline; Pyrrolidines; Quinoxalines; Sulfonamides	2020
Efficacy, Safety, and Predictors of Direct-acting antivirals in Hepatitis C Virus Patients with Heterogeneous Liver Diseases. The new microbiologica, 2019, Volume: 42, Issue:4 Topics: 2-Naphthylamine; Antiviral Agents; Biomarkers, Pharmacological; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Retrospective Studies; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil	2019
Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis. Advances in medical sciences, 2020, Volume: 65, Issue:1 Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Prognosis; Proline; Retrospective Studies; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult	2020
Cost-Effectiveness Analysis of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin Regimen for Patients Infected With Chronic Hepatitis C Virus Genotype 1 in Malaysia. Value in health regional issues, 2020, Volume: 21 Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Genotype; Hepatitis C; Humans; Lactams, Macrocyclic; Malaysia; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine	2020
Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2020, Volume: 26, Issue:9 Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Outcome	2020
Efficacy and safety of glecaprevir/pibrentasvir in patients with hepatitis C virus infection aged ≥75 years. Geriatrics & gerontology international, 2020, Volume: 20, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Japan; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Retrospective Studies; Sulfonamides; Treatment Outcome	2020
Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan. Journal of viral hepatitis, 2020, Volume: 27, Issue:9 Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Taiwan	2020
Renal function in HCV therapy: Just another thing to ignore? Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:5 Topics: Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides	2020
English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed. Alimentary pharmacology & therapeutics, 2020, Volume: 52, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; England; Female; Fluorenes; Hepatitis C; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Registries; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uridine Monophosphate; Valine; Young Adult	2020
Outcomes of the Treatment with Glecaprevir/Pibrentasvir following heart transplantation utilizing hepatitis C viremic donors. Clinical transplantation, 2020, Volume: 34, Issue:9 Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Heart Transplantation; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Sulfonamides; Treatment Outcome; Viremia	2020
Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus. European journal of gastroenterology & hepatology, 2021, 06-01, Volume: 33, Issue:6 Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response	2021
Management and tolerability of glecaprevir-pibrentasvir pharmacotherapy in hepatitis C viremic heart and lung transplant recipients. Clinical transplantation, 2020, Volume: 34, Issue:10 Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Lung; Proline; Pyrrolidines; Quinoxalines; Retrospective Studies; Sulfonamides; Transplant Recipients; Viremia	2020
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 11-02, Volume: 73, Issue:9 Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome	2021
Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R). European journal of gastroenterology & hepatology, 2022, 01-01, Volume: 34, Issue:1 Topics: Amides; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Registries; Renal Insufficiency, Chronic; Ribavirin; Sulfonamides; Sustained Virologic Response	2022
Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study. Journal of acquired immune deficiency syndromes (1999), 2021, 02-01, Volume: 86, Issue:2 Topics: Anilides; Antiviral Agents; Benzimidazoles; Coinfection; Cyclopropanes; Female; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine	2021
Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience? Journal of gastroenterology and hepatology, 2021, Volume: 36, Issue:7 Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Retrospective Studies; Sulfonamides	2021
Hepatitis C and beta-thalassemia major in children: experience with glecaprevir/pibrentasvir. Revista espanola de enfermedades digestivas, 2021, Volume: 113, Issue:2 Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; beta-Thalassemia; Child; China; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides	2021
Feasibility and efficacy of 8 week Glecaprevir/Pibrentasvir to treat incarcerated viraemic HCV patients: A case-control study. Liver international : official journal of the International Association for the Study of the Liver, 2021, Volume: 41, Issue:2 Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Case-Control Studies; Cyclopropanes; Feasibility Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Italy; Lactams, Macrocyclic; Leucine; Middle Aged; Prisoners; Proline; Pyrrolidines; Quinoxalines; Sulfonamides	2021
Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real-world data from the German Hepatitis C-Registry. Liver international : official journal of the International Association for the Study of the Liver, 2021, Volume: 41, Issue:5 Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Registries; Sulfonamides; Sustained Virologic Response	2021
Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report. BMC infectious diseases, 2021, Apr-27, Volume: 21, Issue:1 Topics: Aminoisobutyric Acids; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Benzimidazoles; Cyclophosphamide; Cyclopropanes; Doxorubicin; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Proline; Pyrrolidines; Quinoxalines; Rituximab; RNA, Viral; Sulfonamides; Sustained Virologic Response; Vincristine; Viral Load	2021
Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C-Registry. Liver international : official journal of the International Association for the Study of the Liver, 2021, Volume: 41, Issue:7 Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Registries; Sulfonamides; Sustained Virologic Response	2021
Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts. Advances in therapy, 2021, Volume: 38, Issue:6 Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Neoplasms; Proline; Pyrrolidines; Quinoxalines; Sulfonamides	2021
Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study. Gastroenterologia y hepatologia, 2022, Volume: 45, Issue:5 Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Retrospective Studies; Sulfonamides	2022
Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study. Annals of transplantation, 2017, Apr-07, Volume: 22 Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Postoperative Complications; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine	2017
Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study. Antiviral therapy, 2017, Volume: 22, Issue:8 Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Bilirubin; Biomarkers; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Function Tests; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine	2017
Effectiveness of a fixed combination formula of ombitasvir/paritaprevir/ritonavir for hepatitis C virus infection in patients on maintenance haemodialysis. Nephrology (Carlton, Vic.), 2017, Volume: 22, Issue:7 Topics: Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Disease Progression; Drug Combinations; Drug Compounding; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Japan; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Renal Dialysis; Renal Insufficiency, Chronic; Ritonavir; RNA, Viral; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Viral Load	2017
Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan. Journal of the Formosan Medical Association = Taiwan yi zhi, 2018, Volume: 117, Issue:6 Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Sustained Virologic Response; Taiwan; Viral Load; Young Adult	2018
Managing Drug-Drug Interaction Between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Mycophenolate Mofetil. Therapeutic drug monitoring, 2017, Volume: 39, Issue:4 Topics: 2-Naphthylamine; Aged; Anilides; Antibiotics, Antineoplastic; Antiviral Agents; Carbamates; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Disease Management; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Mycophenolic Acid; Proline; Ritonavir; Sulfonamides; Uracil; Valine	2017
Successful twice interrupted therapy of HCV infection in patients with cirrhosis with hepatocellular carcinoma before and after liver transplantation. BMJ case reports, 2017, Sep-15, Volume: 2017 Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Drug Therapy, Combination; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine	2017
Real-Life Use of 3 Direct-Acting Antiviral Regimen in a Large Cohort of Patients with Genotype-1b HCV Compensated Cirrhosis. Journal of gastrointestinal and liver diseases : JGLD, 2017, Volume: 26, Issue:3 Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ritonavir; Romania; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine	2017
Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real-world data from a large healthcare provider. Journal of viral hepatitis, 2018, Volume: 25, Issue:2 Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine	2018
Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation. Hepatology (Baltimore, Md.), 2018, Volume: 67, Issue:2 Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Risk Assessment; Sofosbuvir; Sulfonamides; Sustained Virologic Response; United States; United States Food and Drug Administration; Viral Nonstructural Proteins	2018
New Oral HCV Drug. The American journal of nursing, 2017, Volume: 117, Issue:11 Topics: Administration, Oral; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Contraindications, Drug; Cyclopropanes; Drug Approval; Drug Combinations; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides	2017
Proton-pump inhibitors and glecaprevir plus pibrentasvir in HCV infection. The Lancet. Infectious diseases, 2017, Volume: 17, Issue:12 Topics: Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Proline; Proton Pump Inhibitors; Protons; Pyrrolidines; Quinoxalines; Sulfonamides	2017
Proton-pump inhibitors and glecaprevir plus pibrentasvir in HCV infection - Authors' reply. The Lancet. Infectious diseases, 2017, Volume: 17, Issue:12 Topics: Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Proline; Proton Pump Inhibitors; Protons; Pyrrolidines; Quinoxalines; Sulfonamides	2017
Mavyret: A Pan-Genotypic Combination Therapy for the Treatment of Hepatitis C Infection Biochemistry, 2018, 02-06, Volume: 57, Issue:5 Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Combinations; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Serine Proteases; Sulfonamides; Viral Nonstructural Proteins	2018
New hepatitis C virus genotype 1 subtype naturally harbouring resistance-associated mutations to NS5A inhibitors. The Journal of general virology, 2018, Volume: 99, Issue:1 Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Drug Resistance, Viral; Equatorial Guinea; Female; Fluorenes; Gene Expression; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Microbial Sensitivity Tests; Middle Aged; Mutation; Phylogeny; Proline; Pyrrolidines; Sequence Analysis, DNA; Sulfonamides; Uracil; Valine; Viral Nonstructural Proteins	2018
Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment. Internal medicine (Tokyo, Japan), 2018, May-01, Volume: 57, Issue:9 Topics: Aged; Anilides; Antiviral Agents; Carbamates; Case-Control Studies; Cyclopropanes; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Hydroxycholesterols; Imidazoles; Interferons; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Pyrrolidines; Ritonavir; Sex Factors; Sulfonamides; Treatment Failure; Valine	2018
Design, synthesis and identification of silicon-containing HCV NS5A inhibitors with pan-genotype activity. European journal of medicinal chemistry, 2018, Mar-25, Volume: 148 Topics: Anilides; Animals; Antiviral Agents; Carbamates; Dogs; Drug Design; Enzyme Inhibitors; Genotype; Hepacivirus; Hepatitis C; Humans; Proline; Silicon; Valine; Viral Nonstructural Proteins	2018
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients. PloS one, 2018, Volume: 13, Issue:2 Topics: 2-Naphthylamine; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis C; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil	2018
The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort. Upsala journal of medical sciences, 2018, Volume: 123, Issue:1 Topics: Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepatitis C; Humans; Middle Aged; Mutation; Oligopeptides; Proline; Protease Inhibitors; Retrospective Studies; Viral Nonstructural Proteins	2018
New Treatment Options for Hepatitis C Virus Infection in End-Stage Kidney Disease: To Treat or Not to Treat. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2018, Volume: 72, Issue:1 Topics: Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Hepacivirus; Hepatitis C; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sulfonamides	2018
Gadoxetic acid-enhanced magnetic resonance imaging to predict paritaprevir-induced hyperbilirubinemia during treatment of hepatitis C. PloS one, 2018, Volume: 13, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Contrast Media; Cyclopropanes; Female; Gadolinium DTPA; Hepatitis C; Humans; Hyperbilirubinemia; Lactams, Macrocyclic; Macrocyclic Compounds; Magnetic Resonance Imaging; Male; Middle Aged; Proline; Prospective Studies; Sulfonamides; Time Factors; Treatment Outcome	2018
Rescue for interferon failures in HCV genotype 1/HBV dually infection. Journal of the Formosan Medical Association = Taiwan yi zhi, 2018, Volume: 117, Issue:9 Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis B virus; Hepatitis C; Humans; Interferons; Proline; Ribavirin; Taiwan	2018
Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia. Gastroenterologia y hepatologia, 2019, Volume: 42, Issue:3 Topics: 2-Naphthylamine; Anemia; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Darbepoetin alfa; Female; Hematinics; Hematocrit; Hemoglobin A; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine	2019
The choice of antiviral therapy for hepatitis C recurrence after liver transplantation in the real world. Journal of the Formosan Medical Association = Taiwan yi zhi, 2018, Volume: 117, Issue:11 Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine	2018
Ombitasvir/paritaprevir/ritonavir+dasabuvir and ribavirin associated drug-induced liver injury and syndrome of inappropriate secretion of anti-diuretic hormone: A case report. Clinical and molecular hepatology, 2019, Volume: 25, Issue:3 Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; Creatinine; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Function Tests; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sodium; Sulfonamides; Uracil; Valine	2019
Fibrosing cholestatic hepatitis in a kidney transplant recipient with hepatitis C virus. CEN case reports, 2019, Volume: 8, Issue:2 Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Bilirubin; Cholestasis; Cyclopropanes; Fatal Outcome; Hepacivirus; Hepatitis C; Humans; Kidney Transplantation; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Transplant Recipients; Viral Load	2019
Public health round-up. Bulletin of the World Health Organization, 2019, Jan-01, Volume: 97, Issue:1 Topics: Adenosine Monophosphate; Alanine; Aminoisobutyric Acids; Anti-Bacterial Agents; Antibodies, Monoclonal; Benzimidazoles; Cyclopropanes; Democratic Republic of the Congo; Disease Outbreaks; Drug Resistance, Bacterial; Global Health; Hemorrhagic Fever, Ebola; Hepatitis C; Humans; Interinstitutional Relations; Lactams, Macrocyclic; Leucine; Malaria; Measles; Measles Vaccine; Poliomyelitis; Proline; Public Health Practice; Pyrrolidines; Quinoxalines; Randomized Controlled Trials as Topic; Ribonucleotides; Sulfonamides; Tuberculosis	2019
Evaluation of brain volume alterations in HCV-infected patients after interferon-free therapy: A pilot study. Journal of the neurological sciences, 2019, Apr-15, Volume: 399 Topics: Adult; Aged; Anilides; Antiviral Agents; Attention; Brain; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Magnetic Resonance Imaging; Male; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Organ Size; Pilot Projects; Proline; Ritonavir; Sulfonamides; Valine	2019
Renal transplantation from seropositive hepatitis C virus donors to seronegative recipients in Spain: a prospective study. Transplant international : official journal of the European Society for Organ Transplantation, 2019, Volume: 32, Issue:7 Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Donor Selection; Female; Graft Rejection; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Kidney Failure, Chronic; Kidney Transplantation; Lactams, Macrocyclic; Leucine; Living Donors; Male; Middle Aged; Patient Safety; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Spain; Sulfonamides; Treatment Outcome	2019
Safety of Hepatitis C Viral Protease Inhibitors in Compensated Cirrhotics: Lingering Concerns Put to Rest? Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 10-30, Volume: 69, Issue:10 Topics: Adult; Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Protease Inhibitors; Pyrrolidines; Quinoxalines; Sulfonamides	2019
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis. Journal of gastroenterology and hepatology, 2019, Volume: 34, Issue:11 Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Renal Dialysis; Ritonavir; Sulfonamides; Valine; Young Adult	2019
Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients. BMC infectious diseases, 2019, May-03, Volume: 19, Issue:1 Topics: Adult; Aged; Aminoisobutyric Acids; Anti-Retroviral Agents; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Cyclopropanes; Drug Interactions; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Outcome; Viral Load	2019
Insights into resistance mechanism of hepatitis C virus nonstructural 3/4A protease mutant to boceprevir using umbrella sampling simulation study. Journal of biomolecular structure & dynamics, 2020, Volume: 38, Issue:7 Topics: Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Peptide Hydrolases; Proline; Protease Inhibitors; Viral Nonstructural Proteins	2020
Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in Japan. Journal of viral hepatitis, 2019, Volume: 26, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Japan; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sequence Analysis, DNA; Sulfonamides; Sustained Virologic Response; Treatment Failure; Treatment Outcome; Young Adult	2019
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world. Journal of hepatology, 2019, Volume: 71, Issue:5 Topics: Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Lactams, Macrocyclic; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Retreatment; Ribavirin; Ritonavir; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Valine; Viral Nonstructural Proteins	2019
Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:11 Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Oligopeptides; Proline	2013
Reply to Calcagno et al. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:11 Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Oligopeptides; Proline	2013
A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. Journal of pharmaceutical and biomedical analysis, 2013, May-05, Volume: 78-79 Topics: Chromatography, Liquid; Hepatitis C; Humans; Isomerism; Limit of Detection; Oligopeptides; Proline; Protease Inhibitors; Reference Standards; Reproducibility of Results; Tandem Mass Spectrometry	2013
Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model. PLoS computational biology, 2013, Volume: 9, Issue:3 Topics: Antiviral Agents; Computational Biology; Cyclopropanes; Hepacivirus; Hepatitis C; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Models, Biological; Proline; RNA, Viral; Sulfonamides; Virus Replication	2013
Mixed genotype hepatitis C infections and implications for treatment. Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:3 Topics: Antiviral Agents; Drug Resistance, Viral; Genotype; Hepatitis C; Humans; Oligopeptides; Prevalence; Proline	2014
Pretreatment resistance to hepatitis C virus protease inhibitors boceprevir/telaprevir in hepatitis C virus subgenotype 1a-infected patients from Manitoba. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2013, Volume: 27, Issue:7 Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Indians, North American; Male; Manitoba; Middle Aged; Mutation; Oligopeptides; Proline; Protease Inhibitors; Sequence Analysis, DNA; Viral Nonstructural Proteins; Young Adult	2013
Polypharmacy and comorbidity are associated with a lower early virologic response in hepatitis C patients treated with first generation protease inhibitor triple therapy: a preliminary analysis. Digestive diseases and sciences, 2013, Volume: 58, Issue:11 Topics: Adult; Aged; Antiviral Agents; Drug Interactions; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Oligopeptides; Polypharmacy; Proline; Retrospective Studies; Ribavirin; Viral Load	2013
The discovery and development of boceprevir. Expert opinion on drug discovery, 2013, Volume: 8, Issue:11 Topics: Antiviral Agents; Drug Discovery; Hepatitis C; Humans; Molecular Targeted Therapy; Proline; Protease Inhibitors; Structure-Activity Relationship; Viral Nonstructural Proteins	2013
Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor. Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:6 Topics: Antiviral Agents; Contraindications; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Viral Load	2014
Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:1 Topics: Antiviral Agents; Cohort Studies; Comparative Effectiveness Research; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Thrombocytopenia; United States; Veterans	2014
EASL Clinical Practice Guidelines: management of hepatitis C virus infection. Journal of hepatology, 2014, Volume: 60, Issue:2 Topics: Antiviral Agents; Contraindications; Drug Monitoring; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Ribavirin	2014
Prevalence of hepatitis C virus mutants resistant to protease inhibitors among Polish HCV genotype 1-infected patients. Przeglad epidemiologiczny, 2013, Volume: 67, Issue:3 Topics: Antiviral Agents; Drug Resistance, Viral; Female; Genetics, Population; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Mutation; Oligopeptides; Prevalence; Proline; Protease Inhibitors; Sequence Analysis	2013
Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Volume: 58, Issue:7 Topics: Aminoisobutyric Acids; Anti-HIV Agents; Antiviral Agents; Carbamates; Developing Countries; Drug Industry; Drug Therapy, Combination; Health Services Accessibility; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Leucine; Oligopeptides; Proline; Pyrrolidines; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate; Valine	2014
Liver transplantation in a child with multifocal hepatocellular carcinoma hepatitis C and management of post-transplant viral recurrence using boceprevir. Pediatric transplantation, 2014, Volume: 18, Issue:2 Topics: Adolescent; Carcinoma, Hepatocellular; Child; Graft Survival; Hepatitis C; Humans; Interferons; Liver Neoplasms; Liver Transplantation; Male; Polyethylene Glycols; Postoperative Complications; Proline; Recurrence; Ribavirin; Severe Combined Immunodeficiency	2014
Hepatitis C treatment & management. Journal of medicine and life, 2014, Mar-15, Volume: 7, Issue:1 Topics: Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Recurrence; Ribavirin; Sofosbuvir; Time Factors; Uridine Monophosphate	2014
Impact of provider type on hepatitis C outcomes with boceprevir-based and telaprevir-based regimens. Journal of clinical gastroenterology, 2015, Volume: 49, Issue:4 Topics: Antiviral Agents; Cohort Studies; Female; Genotype; Health Personnel; Hematologic Diseases; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Oligopeptides; Proline; Retrospective Studies; Treatment Outcome; Veterans; Viral Load	2015
Boceprevir in liver transplant recipients. Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:1 Topics: Adult; Aged; Analysis of Variance; Creatinine; Drug Monitoring; Female; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Transplant Recipients	2015
The position of the Sociedad Española de Patología Digestiva on the current situation of hepatitis C management in Spain. Revista espanola de enfermedades digestivas, 2014, Volume: 106, Issue:1 Topics: Antiviral Agents; Hepatitis C; Humans; Oligopeptides; Proline; Spain	2014
A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. Journal of hepatology, 2014, Volume: 61, Issue:3 Topics: Adult; Aged; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; United States	2014
Letter: Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis. Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:11 Topics: Antiviral Agents; Female; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin	2014
Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents. PLoS pathogens, 2014, Volume: 10, Issue:5 Topics: Antibodies, Neutralizing; Antiviral Agents; Carbamates; Cell Communication; Cells, Cultured; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Imidazoles; Oligopeptides; Proline; Pyrrolidines; Valine; Viral Load; Virus Internalization	2014
A population approach to disease management: hepatitis C direct-acting antiviral use in a large health care system. Journal of managed care & specialty pharmacy, 2014, Volume: 20, Issue:6 Topics: Anemia; Antiviral Agents; Biomarkers; Comparative Effectiveness Research; Delivery of Health Care; Drug Prescriptions; Drug Therapy, Combination; Education, Medical, Continuing; Education, Pharmacy, Continuing; Guideline Adherence; Hematinics; Hepacivirus; Hepatitis C; Humans; Medication Therapy Management; Oligopeptides; Pharmaceutical Services; Practice Guidelines as Topic; Practice Patterns, Physicians'; Proline; Registries; RNA, Viral; Time Factors; Treatment Outcome; United States; United States Department of Veterans Affairs; Viral Load	2014
[Treatment of hepatitis C: current status and perspectives]. La Revue du praticien, 2014, Volume: 64, Issue:5 Topics: Antiviral Agents; Drug Therapy, Combination; Evidence-Based Medicine; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Practice Guidelines as Topic; Proline; Protease Inhibitors; Ribavirin; Treatment Outcome	2014
A case of successful treatment with telaprevir-based triple therapy for hepatitis C infection after treatment failure with vaniprevir-based triple therapy. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2014, Volume: 20, Issue:9 Topics: Aged; Antiviral Agents; Cyclopropanes; Hepacivirus; Hepatitis C; Humans; Indoles; Isoindoles; Lactams, Macrocyclic; Leucine; Male; Oligopeptides; Proline; Sulfonamides; Treatment Failure	2014
Predicting the probability of experiencing clinically significant drug-drug interactions involving boceprevir-containing hepatitis C therapy among patients coinfected with hepatitis C and HIV. AIDS patient care and STDs, 2014, Volume: 28, Issue:10 Topics: Adult; Coinfection; Cross-Sectional Studies; Drug Interactions; Female; Hepatitis C; HIV Infections; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; New York; Probability; Proline; Protease Inhibitors; Treatment Outcome	2014
PPARγ2 Pro12Ala polymorphism was associated with favorable cardiometabolic risk profile in HIV/HCV coinfected patients: a cross-sectional study. Journal of translational medicine, 2014, Aug-27, Volume: 12 Topics: Adult; Alanine; Amino Acid Substitution; Cardiovascular Diseases; Coinfection; Cross-Sectional Studies; Female; Genetic Predisposition to Disease; Hepatitis C; HIV Infections; HIV-1; Humans; Male; Metabolic Diseases; Metabolome; Middle Aged; Polymorphism, Single Nucleotide; PPAR gamma; Proline; Risk Factors	2014
Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations. Antiviral therapy, 2015, Volume: 20, Issue:3 Topics: Amino Acid Substitution; Antiviral Agents; Cell Line, Tumor; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Conformation; Mutation; Proline; Recombination, Genetic; Replicon; Viral Nonstructural Proteins; Virus Replication	2015
Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. PloS one, 2014, Volume: 9, Issue:11 Topics: Anti-Retroviral Agents; Clinical Laboratory Techniques; Europe; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Oligopeptides; Predictive Value of Tests; Proline; Protease Inhibitors; Reproducibility of Results; RNA, Viral; Treatment Outcome; Viremia	2014
Provider Workforce Assessment in a Rural Hepatitis C Epidemic: Implications for Scale-up of Antiviral Therapy. Journal of primary care & community health, 2015, Volume: 6, Issue:3 Topics: Antiviral Agents; Health Services Accessibility; Hepatitis C; Humans; Oligopeptides; Practice Patterns, Physicians'; Primary Health Care; Proline; Rural Health; Rural Health Services; Wisconsin	2015
In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:2 Topics: Anilides; Antiviral Agents; Carbamates; Cell Line; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Proline; Valine	2015
Dasabuvir : a new direct antiviral agent for the treatment of hepatitis C. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:4 Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Lactams, Macrocyclic; Macrocyclic Compounds; Polyethylene Glycols; Proline; Ribavirin; RNA-Dependent RNA Polymerase; Sulfonamides; Uracil; Valine	2015
Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. Transplantation, 2015, Volume: 99, Issue:8 Topics: Antiviral Agents; Biomarkers; Cholestasis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Oligopeptides; Proline; Recurrence; Retrospective Studies; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; United States; Viral Load	2015
Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study. World journal of gastroenterology, 2015, Mar-14, Volume: 21, Issue:10 Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Predictive Value of Tests; Proline; Prospective Studies; Ribavirin; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load	2015
Hepatitis C virus NS5A protein blocks epidermal growth factor receptor degradation via a proline motif- dependent interaction. The Journal of general virology, 2015, Volume: 96, Issue:8 Topics: Amino Acid Motifs; Endocytosis; ErbB Receptors; Hepacivirus; Hepatitis C; Humans; Proline; Protein Binding; Protein Transport; Proteolysis; Viral Nonstructural Proteins	2015
A 4-drug combination (Viekira Pak) for hepatitis C. JAMA, 2015, May-12, Volume: 313, Issue:18 Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Drug Combinations; Drug Interactions; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Uracil; Valine	2015
Boceprevir: serious haematological disorders. Prescrire international, 2014, Volume: 23, Issue:153 Topics: Antiviral Agents; Drug Monitoring; Hematologic Diseases; Hepatitis C; Humans; Predictive Value of Tests; Proline; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome	2014
THE ABSENCE OF THYROID DISEASE IN AN AUSTRALIAN HEPATITIS C COHORT TREATED WITH TRIPLE COMBINATION THERAPY: A PARADIGM SHIFT. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2015, Volume: 21, Issue:9 Topics: Adult; Australia; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Retrospective Studies; Ribavirin; Thyroid Diseases	2015
ITPA and SLC29A1 Genotyping for the Prediction of Ribavirin Dose Reduction in Anti-HCV Triple Therapy with Protease Inhibitors. Pharmacology, 2015, Volume: 96, Issue:3-4 Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Equilibrative Nucleoside Transporter 1; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Proline; Protease Inhibitors; Pyrophosphatases; Ribavirin	2015
UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells. Journal of pharmaceutical and biomedical analysis, 2015, Nov-10, Volume: 115 Topics: Antiviral Agents; Automation, Laboratory; Chromatography, Liquid; Drug Monitoring; Hepatitis C; Humans; Isomerism; Leukocytes, Mononuclear; Limit of Detection; Linear Models; Oligopeptides; Proline; Reference Standards; Reproducibility of Results; Solid Phase Extraction; Tandem Mass Spectrometry; Time Factors	2015
Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients. PloS one, 2015, Volume: 10, Issue:9 Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medical Futility; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Taiwan; Treatment Outcome	2015
Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future? PloS one, 2015, Volume: 10, Issue:9 Topics: Adult; Aged; Anemia; Antiviral Agents; Combined Modality Therapy; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Host-Pathogen Interactions; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Postoperative Period; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Recurrence; Thrombocytopenia; Treatment Outcome	2015
Paritaprevir/ritonavir, ombitasvir, and dasabuvir for treatment of recurrent hepatitis C virus infection in the human immunodeficiency virus coinfected liver transplant recipient. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2016, Volume: 22, Issue:2 Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Genotype; Graft Survival; Hepacivirus; Hepatitis C; HIV Infections; Humans; Immunosuppressive Agents; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Proline; Recurrence; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Uracil; Valine	2016
HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2015, Volume: 73 Topics: Antiviral Agents; Coinfection; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; Treatment Outcome; Viral Load	2015
Safety of rilpivirine and boceprevir coadministration in HIV-infected patients treated for acute hepatitis C virus infection. AIDS (London, England), 2016, Jan-28, Volume: 30, Issue:3 Topics: Adult; Antiviral Agents; Drug Interactions; Hepatitis C; HIV Infections; Humans; Male; Netherlands; Plasma; Proline; Rilpivirine	2016
Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice. Virus research, 2016, Feb-02, Volume: 213 Topics: Animals; Antiviral Agents; Cell Line; Cyclopropanes; Disease Models, Animal; Drug Resistance, Viral; Drug Therapy, Combination; Gene Expression Profiling; Hepacivirus; Hepatitis C; Hepatocytes; High-Throughput Nucleotide Sequencing; Humans; Indoles; Isoindoles; Lactams, Macrocyclic; Leucine; Mice; Mice, Transgenic; Mutation, Missense; Proline; RNA, Viral; Sulfonamides; Treatment Outcome; Virus Replication	2016
Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV. Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:4 Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug Costs; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Male; Markov Chains; Middle Aged; Models, Economic; Phenotype; Proline; Recurrence; Ribavirin; Risk Factors; Ritonavir; Sulfonamides; Time Factors; Treatment Outcome; United States; Uracil; Valine; Viral Load; Virus Activation	2016
Boceprevir, peginterferon and ribavirin for acute hepatitis C in HIV infected patients. Journal of hepatology, 2016, Volume: 64, Issue:4 Topics: Acute Disease; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin	2016
Severe Hyperbilirubinemia in an HIV-HCV-Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction. Therapeutic drug monitoring, 2016, Volume: 38, Issue:3 Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Atazanavir Sulfate; Carbamates; Coinfection; Cyclopropanes; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Ritonavir; Sulfonamides; Uracil; Valine	2016
Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma. World journal of gastroenterology, 2016, Feb-28, Volume: 22, Issue:8 Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Function Tests; Liver Neoplasms; Macrocyclic Compounds; Male; Proline; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Uracil; Valine; Viral Load	2016
Darunavir-based Antiretroviral Therapy may Affect the Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in HCV/HIV-1 Coinfected Patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, 07-15, Volume: 63, Issue:2 Topics: 2-Naphthylamine; Anilides; Carbamates; Coinfection; Cyclopropanes; Darunavir; Hepatitis C; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Uracil; Valine	2016
Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. Gastroenterology, 2016, Volume: 151, Issue:3 Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; United States; United States Department of Veterans Affairs; Uracil; Uridine Monophosphate; Valine	2016
Development and validation of a UPLC-MS/MS method for the simultaneous determination of paritaprevir and ritonavir in rat liver. Bioanalysis, 2016, Volume: 8, Issue:13 Topics: Animals; Antiviral Agents; Chromatography, High Pressure Liquid; Cyclopropanes; Hepacivirus; Hepatitis C; Lactams, Macrocyclic; Limit of Detection; Liver; Macrocyclic Compounds; Male; Pilot Projects; Proline; Protease Inhibitors; Rats; Rats, Sprague-Dawley; Ritonavir; Sulfonamides; Tandem Mass Spectrometry	2016
Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2016, Volume: 19, Issue:4 Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug Combinations; Female; Fluorenes; Health Services Accessibility; Hepacivirus; Hepatitis C; HIV Protease Inhibitors; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Markov Chains; Medicaid; Middle Aged; Proline; Ritonavir; Severity of Illness Index; Sofosbuvir; Sulfonamides; United States; Uracil; Uridine Monophosphate; Valine	2016
Breast Hypertrophy Induced by Ombitasvir/Paritaprevir/Ritonavir and Ribavirina. The breast journal, 2016, Volume: 22, Issue:6 Topics: Anilides; Antiviral Agents; Breast Diseases; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C; Humans; Hypertrophy; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Valine	2016
[FIRST GENERATION PROTEASE INHIBITOR BASED TRIPLE THERAPY FOR HCV GENOTYPE 1--LOOKING BACK WHILE PROCEEDING TO A PROMISING ERA]. Harefuah, 2016, Volume: 155, Issue:5 Topics: Adult; Antiviral Agents; DNA, Viral; Drug Carriers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Israel; Male; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome	2016
[Efficacy and safety of boceprevir based triple therapy in Hungarian patients with hepatitis C genotype 1 infection, advanced stage fibrosis and prior treatment failure]. Orvosi hetilap, 2016, Volume: 157, Issue:34 Topics: Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Hungary; Interferon-alpha; Liver Cirrhosis; Proline; Treatment Outcome	2016
Reply to: Danoprevir pharmacokinetic/viral kinetic model for treating chronic HCV - some considerations. Antiviral therapy, 2016, Volume: 21, Issue:7 Topics: Cyclopropanes; Hepatitis C; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Proline; Sulfonamides	2016
Danoprevir pharmacokinetic/viral kinetic model for treating chronic HCV - some considerations. Antiviral therapy, 2016, Volume: 21, Issue:7 Topics: Antiviral Agents; Cyclopropanes; Hepatitis C; Hepatitis C, Chronic; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Models, Biological; Proline; Sulfonamides	2016
Falling up stairs. Australian family physician, 2016, Volume: 45, Issue:9 Topics: 2-Naphthylamine; Accidental Falls; Anilides; Antiviral Agents; Bronchodilator Agents; Carbamates; Cushing Syndrome; Cyclopropanes; Drug Therapy, Combination; Fluticasone; Hepatitis C; Humans; Hydrocortisone; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Salmeterol Xinafoate; Sulfonamides; Uracil; Valine	2016
Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials. British journal of clinical pharmacology, 2017, Volume: 83, Issue:3 Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Combinations; Female; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Models, Biological; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Young Adult	2017
First Case in Kazakhstan of Successful Therapy With 2 Consecutive Direct-Acting Antiviral Regimens in a Patient with Hepatitis C Virus-Induced Decompensated Liver Cirrhosis on a Liver Transplant Wait List. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2016, Volume: 14, Issue:Suppl 3 Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C; Humans; Kazakhstan; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Male; Medication Adherence; Proline; Recurrence; Retreatment; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine; Waiting Lists	2016
Hepatitis C Treatment With Direct-Acting Antivirals in Kidney Transplant: Preliminary Results From a Multicenter Study. Transplantation proceedings, 2016, Volume: 48, Issue:9 Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunosuppression Therapy; Kidney Transplantation; Lactams, Macrocyclic; Macrocyclic Compounds; Postoperative Complications; Proline; Prospective Studies; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Spain; Sulfonamides; Treatment Outcome; Valine	2016
Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis Infected with Hepatitis C Virus Genotypes 1 and 4. American journal of nephrology, 2017, Volume: 45, Issue:3 Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Renal Dialysis; Ribavirin; Ritonavir; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine	2017
Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017, Jun-15, Volume: 64, Issue:12 Topics: Administration, Oral; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Practice Patterns, Physicians'; Proline; Registries; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Valine; Veterans	2017
Hepatitis C virus NS3-4A serine protease inhibitors: SAR of new P1 derivatives of SCH 503034. Bioorganic & medicinal chemistry letters, 2008, Jul-15, Volume: 18, Issue:14 Topics: Area Under Curve; Chemistry, Pharmaceutical; Drug Design; Fluorine; Hepatitis C; Humans; Inhibitory Concentration 50; Kinetics; Models, Chemical; Molecular Conformation; Proline; Serine Proteinase Inhibitors; Stereoisomerism; Structure-Activity Relationship; Viral Nonstructural Proteins	2008
[The 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), Milan, Italy, April 23-27, 2008]. Orvosi hetilap, 2008, Jul-13, Volume: 149, Issue:28 Topics: Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Delayed-Action Preparations; Europe; Hepatitis B; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Diseases; Liver Neoplasms; Niacinamide; Oligopeptides; Patient Compliance; Phenylurea Compounds; Polyethylene Glycols; Proline; Pyridines; Recombinant Proteins; Ribavirin; Societies, Medical; Sorafenib	2008
Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antiviral therapy, 2008, Volume: 13, Issue:4 Topics: Amino Acid Sequence; Antiviral Agents; Carbamates; Carrier Proteins; Drug Resistance, Viral; Global Health; Hepacivirus; Hepatitis C; Humans; Intracellular Signaling Peptides and Proteins; Macrocyclic Compounds; Microbial Sensitivity Tests; Molecular Sequence Data; Oligopeptides; Polymorphism, Genetic; Proline; Protease Inhibitors; Quinolines; Sequence Alignment; Thiazoles; Viral Nonstructural Proteins; Viral Proteins	2008
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (Baltimore, Md.), 2008, Volume: 48, Issue:6 Topics: Antiviral Agents; Carbamates; Cohort Studies; Drug Resistance, Viral; Female; Genetic Testing; Hepacivirus; Hepatitis C; Humans; Macrocyclic Compounds; Male; Mutation; Oligopeptides; Phenylthiourea; Phylogeny; Proline; Protease Inhibitors; Quinolines; Thiazoles; Viral Load; Viral Nonstructural Proteins	2008
Hepatitis C drug development at a crossroads. Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:4 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome	2009
Potent ketoamide inhibitors of HCV NS3 protease derived from quaternized P1 groups. Bioorganic & medicinal chemistry letters, 2010, Apr-01, Volume: 20, Issue:7 Topics: Amides; Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Proline; Protease Inhibitors; Structure-Activity Relationship; Viral Nonstructural Proteins	2010
New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. The Journal of antimicrobial chemotherapy, 2010, Volume: 65, Issue:6 Topics: Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Deoxycytidine; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Oligopeptides; Proline	2010
Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors. Journal of viral hepatitis, 2011, Volume: 18, Issue:5 Topics: Antiviral Agents; Blood Proteins; Carbamates; Cell Line; Comparative Effectiveness Research; Dialysis; Hepacivirus; Hepatitis C; Humans; Inhibitory Concentration 50; Macrocyclic Compounds; Membranes, Artificial; Oligopeptides; Phenylthiourea; Plasma; Proline; Protease Inhibitors; Protein Binding; Quinolines; RNA, Viral; Thiazoles; Viral Load	2011
Excitement grows for potential revolution in hepatitis C virus treatment. Nature reviews. Drug discovery, 2010, Volume: 9, Issue:7 Topics: Antiviral Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Oligopeptides; Proline; Protease Inhibitors	2010
On the cusp of change: new therapeutic modalities for HCV. Annals of hepatology, 2010, Volume: 9 Suppl Topics: Antiviral Agents; Clinical Trials as Topic; Drug Costs; Drug Therapy, Combination; Drugs, Investigational; Evidence-Based Medicine; Hepatitis C; Humans; Oligopeptides; Patient Selection; Proline; Treatment Outcome; Viral Load	2010
Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection. Current opinion in investigational drugs (London, England : 2000), 2010, Volume: 11, Issue:8 Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Cyclopropanes; Dogs; Drug Evaluation, Preclinical; Drug Therapy, Combination; Haplorhini; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Polyethylene Glycols; Proline; Protease Inhibitors; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Ribavirin; Ritonavir; Sulfonamides; Viral Nonstructural Proteins	2010
Big changes are coming in hepatitis C. Current gastroenterology reports, 2011, Volume: 13, Issue:1 Topics: Administration, Oral; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Hepatitis C; Humans; Interferons; Oligopeptides; Proline; Protease Inhibitors; Ribavirin	2011
The role of triple therapy in HCV genotype 1-experienced patients. Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31 Suppl 1 Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin	2011
The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. Gastroenterology, 2011, Volume: 140, Issue:3 Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Evidence-Based Medicine; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Patient Selection; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load	2011
Combined X-ray, NMR, and kinetic analyses reveal uncommon binding characteristics of the hepatitis C virus NS3-NS4A protease inhibitor BI 201335. The Journal of biological chemistry, 2011, Apr-01, Volume: 286, Issue:13 Topics: Aminoisobutyric Acids; Carrier Proteins; Catalytic Domain; Clinical Trials, Phase I as Topic; Crystallography, X-Ray; Hepacivirus; Hepatitis C; Humans; Intracellular Signaling Peptides and Proteins; Leucine; Nuclear Magnetic Resonance, Biomolecular; Oligopeptides; Proline; Protease Inhibitors; Protein Binding; Quinolines; Thiazoles; Viral Nonstructural Proteins	2011
Drugs in development for viral hepatitis: care and caution. Drugs, 2011, Feb-12, Volume: 71, Issue:3 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis, Viral, Human; Humans; Oligopeptides; Proline	2011
Distributive justice and the arrival of direct-acting antivirals: who should be first in line? Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:6 Topics: Algorithms; Antiviral Agents; Health Care Rationing; Hepatitis C; Humans; Oligopeptides; Proline; Resource Allocation; United States; United States Food and Drug Administration	2011
Introduction: a smouldering public-health crisis. Nature, 2011, Jun-08, Volume: 474, Issue:7350 Topics: Adolescent; France; Global Health; Hepacivirus; Hepatitis C; HIV Infections; Humans; Oligopeptides; Proline; Public Health; Viral Hepatitis Vaccines; Young Adult	2011
Therapeutics: new drugs hit the target. Nature, 2011, Jun-08, Volume: 474, Issue:7350 Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Oligopeptides; Proline; Ribavirin; Simeprevir; Sulfonamides	2011
Viral hepatitis: progress and promise. Nature reviews. Gastroenterology & hepatology, 2011, Volume: 8, Issue:5 Topics: Antiviral Agents; Hepatitis B; Hepatitis C; Humans; Oligopeptides; Patient Compliance; Pharmacogenetics; Proline; Treatment Outcome	2011
Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology, 2011, Volume: 141, Issue:3 Topics: Carcinoma, Hepatocellular; Carrier Proteins; Cell Line, Tumor; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Isoindoles; Lactams; Lactams, Macrocyclic; Leucine; Liver Neoplasms; Molecular Sequence Data; Oligopeptides; Proline; Protease Inhibitors; Sulfonamides; Treatment Outcome; Viral Nonstructural Proteins	2011
Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents--a potentially lethal cocktail. Hepatology (Baltimore, Md.), 2011, Volume: 54, Issue:1 Topics: Antiviral Agents; Cyclosporine; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Hepatitis C; Humans; Immunosuppressive Agents; Liver Transplantation; Oligopeptides; Proline; Tacrolimus	2011
New Merck and Vertex drugs raise standard of care in hepatitis C. Nature biotechnology, 2011, Jul-11, Volume: 29, Issue:7 Topics: Antiviral Agents; Drug Industry; Hepatitis C; Humans; Oligopeptides; Proline; Quality of Health Care; United States	2011
Telaprevir (Incivek) and boceprevir (Victrelis) for chronic hepatitis C. The Medical letter on drugs and therapeutics, 2011, Jul-25, Volume: 53, Issue:1369 Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin	2011
FDA Advisory Committee reviews safety of boceprevir. AIDS patient care and STDs, 2011, Volume: 25, Issue:6 Topics: Anemia; Bone Marrow; Hepatitis C; Humans; Proline; Protease Inhibitors; United States; United States Food and Drug Administration	2011
Going viral. Scientific American, 2011, Volume: 305, Issue:2 Topics: Anti-HIV Agents; Drug Approval; Hepatitis C; Humans; Oligopeptides; Proline	2011
Will direct-acting antivirals make a difference in HIV-HCV coinfected patients? Expert review of anti-infective therapy, 2011, Volume: 9, Issue:9 Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Coinfection; Drug Interactions; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferons; Oligopeptides; Proline; Ribavirin; Serine Proteases; Serine Proteinase Inhibitors; Viral Proteins	2011
[New treatments for hepatitis C, which targets, what timeline?]. Revue medicale suisse, 2011, Sep-07, Volume: 7, Issue:307 Topics: Antiviral Agents; Hepatitis C; Humans; Oligopeptides; Proline	2011
Specific detection of naturally occurring hepatitis C virus mutants with resistance to telaprevir and boceprevir (protease inhibitors) among treatment-naïve infected individuals. Journal of clinical microbiology, 2012, Volume: 50, Issue:2 Topics: Adult; Antiviral Agents; Biota; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Mutation; Oligopeptides; Polymerase Chain Reaction; Proline; Virology	2012
[Boceprevir-benefit assessment by the Institute for Quality and Efficiency in Health Care (IQWiG) in accordance with Â§ 35a SGB V (dosage evaluation)]. Zeitschrift fur Gastroenterologie, 2012, Volume: 50, Issue:1 Topics: Antiviral Agents; Evidence-Based Medicine; Gastroenterology; Germany; Hepatitis C; Humans; Outcome Assessment, Health Care; Practice Guidelines as Topic; Prevalence; Proline; Risk Assessment; Risk Factors; Treatment Outcome	2012
Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b. Journal of viral hepatitis, 2012, Volume: 19, Issue:2 Topics: Amino Acid Substitution; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Mutation, Missense; Polyethylene Glycols; Proline; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Treatment Failure; Viral Nonstructural Proteins	2012
New hepatitis C regimen stimulates changes in therapy management. Managed care (Langhorne, Pa.), 2011, Volume: 20, Issue:12 Topics: Anemia; Antiviral Agents; Disease Management; Drug Interactions; Hematinics; Hepatitis C; Humans; Oligopeptides; Proline; Protease Inhibitors; Standard of Care	2011
Insight into the structural requirements of narlaprevir-type inhibitors of NS3/NS4A protease based on HQSAR and molecular field analyses. Combinatorial chemistry & high throughput screening, 2012, Volume: 15, Issue:6 Topics: Antiviral Agents; Carrier Proteins; Cyclopropanes; Dipeptides; Drug Design; Hepacivirus; Hepatitis C; Humans; Intracellular Signaling Peptides and Proteins; Leucine; Models, Molecular; Proline; Quantitative Structure-Activity Relationship; Sulfones; Urea; Viral Nonstructural Proteins	2012
[Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis]. Orvosi hetilap, 2012, Mar-11, Volume: 153, Issue:10 Topics: Adenine; Antiviral Agents; Comorbidity; Consensus; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Guanine; Hepacivirus; Hepatitis B; Hepatitis C; Hepatitis D; Humans; Hungary; Interferon-alpha; Interferons; Lamivudine; Oligopeptides; Organophosphonates; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Tenofovir; Time Factors; Treatment Outcome	2012
Efficient, chemoenzymatic process for manufacture of the Boceprevir bicyclic [3.1.0]proline intermediate based on amine oxidase-catalyzed desymmetrization. Journal of the American Chemical Society, 2012, Apr-11, Volume: 134, Issue:14 Topics: Antiviral Agents; Catalysis; Catalytic Domain; Chemistry, Pharmaceutical; Drug Design; Hepatitis C; Humans; Kinetics; Monoamine Oxidase; Oxygen; Proline; Reproducibility of Results; Temperature	2012
Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:3 Topics: Cost-Benefit Analysis; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline	2012
Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:5 Topics: Adult; Antiviral Agents; Area Under Curve; Cyclosporine; Dose-Response Relationship, Drug; Drug Interactions; Female; Hepatitis C; Humans; Immunosuppressive Agents; Male; Proline; Protease Inhibitors; Tacrolimus; Young Adult	2012
Hepatitis drug reduces effects of HIV medications. JAMA, 2012, May-23, Volume: 307, Issue:20 Topics: Antiviral Agents; Drug Interactions; Hepatitis C; HIV Infections; Humans; Proline; Protease Inhibitors; United States; United States Food and Drug Administration; Viral Load	2012
Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor. Bulletin of mathematical biology, 2012, Volume: 74, Issue:8 Topics: Cell Proliferation; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Models, Genetic; Mutation; Numerical Analysis, Computer-Assisted; Oligopeptides; Proline; Protease Inhibitors	2012
The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS pathogens, 2012, Volume: 8, Issue:7 Topics: Antiviral Agents; Cyclopropanes; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Indoles; Isoindoles; Lactams; Lactams, Macrocyclic; Leucine; Models, Molecular; Oligopeptides; Proline; Protease Inhibitors; Protein Structure, Tertiary; Structure-Activity Relationship; Sulfonamides; Viral Nonstructural Proteins	2012
Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase? Journal of hepatology, 2013, Volume: 58, Issue:2 Topics: Antiviral Agents; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome	2013
Treatment of hepatitis C in patients infected with human immunodeficiency virus in the direct-acting antiviral era. Infectious disease clinics of North America, 2012, Volume: 26, Issue:4 Topics: Antiviral Agents; Coinfection; Drug Resistance, Viral; Hepacivirus; Hepatitis C; HIV Infections; Humans; Oligopeptides; Proline	2012
Hepatitis C in 2012. South Dakota medicine : the journal of the South Dakota State Medical Association, 2012, Volume: 65, Issue:11 Topics: Antiviral Agents; Drug Therapy, Combination; Gastroenterology; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Proline; Ribavirin	2012
Hepatitis C infection and presence of advanced fibrosis: wait or treat? Why wait? There is no time to lose, is there? Journal of hepatology, 2013, Volume: 58, Issue:3 Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin	2013
Phenotypic analysis of NS5A variant from liver transplant patient with increased cyclosporine susceptibility. Virology, 2013, Feb-20, Volume: 436, Issue:2 Topics: Amino Acid Sequence; Antiviral Agents; Cyclosporine; DNA Mutational Analysis; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Molecular Sequence Data; Mutation, Missense; Point Mutation; Proline; Transplantation; Viral Nonstructural Proteins; Virus Replication	2013
The antimalarial ferroquine is an inhibitor of hepatitis C virus. Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:1 Topics: Aminoquinolines; Antiviral Agents; Cell Line, Tumor; Drug Synergism; Ferrous Compounds; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Metallocenes; Proline; Viral Envelope Proteins; Viral Nonstructural Proteins; Virus Internalization; Virus Replication	2013
Is the HCV pipeline heading in the right direction? Gastroenterology, 2013, Volume: 144, Issue:3 Topics: Antiviral Agents; Coinfection; Drug Discovery; Health Services Accessibility; Hepatitis C; HIV Infections; Humans; Liver Cirrhosis; Liver Transplantation; Off-Label Use; Oligopeptides; Proline; Treatment Outcome	2013
Current management of hepatitis C virus infection in patients with HIV co-infection. The Journal of infectious diseases, 2013, Volume: 207 Suppl 1 Topics: Antiviral Agents; Clinical Trials as Topic; Coinfection; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Male; Oligopeptides; Proline; Treatment Outcome	2013
Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variants. Bioorganic & medicinal chemistry letters, 2004, Apr-19, Volume: 14, Issue:8 Topics: Carrier Proteins; Hepatitis C; Intracellular Signaling Peptides and Proteins; Models, Molecular; Molecular Structure; Oligopeptides; Proline; Structure-Activity Relationship; Viral Nonstructural Proteins; Viral Proteins	2004
Treatment of hepatitis C: don't put all your eggs in one basket! Gastroenterology, 2007, Volume: 132, Issue:4 Topics: Antiviral Agents; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Proline; Recombinant Proteins; RNA, Viral; Treatment Outcome	2007
Critical point mutations for hepatitis C virus NS3 proteinase. Virology, 1998, Jun-20, Volume: 246, Issue:1 Topics: Amino Acid Sequence; Amino Acid Substitution; Arginine; Binding Sites; DNA, Complementary; Escherichia coli; Hepacivirus; Hepatitis C; Humans; Molecular Sequence Data; Point Mutation; Proline; Protein Conformation; RNA Helicases; RNA, Viral; Sequence Alignment; Sequence Deletion; Serine Endopeptidases; Viral Nonstructural Proteins	1998